1,3,6-substituted indole derivatives having inhibitory activity for protein kinase

ABSTRACT

Disclosed are a 1,3,6-substituted indole compound having inhibitory activity for protein kinases, a pharmaceutically acceptable thereof, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth including the compound as an active ingredient. 
     Since the novel indole compound exhibits superior inhibitory activity for various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating cancers caused by abnormal cell growth.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No.12/858,114 filed Aug. 17, 2010 which claims priority under 35 U.S.C.§119 to Korean Patent Application No. 10-2009-0077185, filed Aug. 20,2009, in the Korean Intellectual Property Office, the disclosures ofwhich are all incorporated herein by reference in their entirety.

TECHNICAL FIELD

The following disclosure relates to a 1,3,6-substituted indole compoundhaving inhibitory activity for protein kinases, a pharmaceuticallyacceptable salts thereof, and a pharmaceutical composition forprevention and treatment of diseases caused by abnormal cell growthincluding the compound as an active ingredient.

BACKGROUND

A protein kinase is an enzyme which catalyzes phosphorylation ofhydroxyl groups on tyrosine, serine and threonine residues of proteins.It plays an important role in signal transduction of growth factorsinvolved in growth, differentiation and proliferation of cells.

For maintenance of homeostasis, it is essential that turning on and offof the signal transduction system be well balanced. However, mutation oroverexpression of specific protein kinases disrupts the signaltransduction system in normal cells (a state when in vivo signaltransduction is continuously turned on) and causes various kinds ofdiseases including cancers, inflammations, metabolic diseases, braindiseases, or the like. Typical protein kinases that lead to diseasescaused by abnormal cell growth include Raf, KDR, Fms, Tie2, SAPK2a, Ret,Abl, Abl(T315I), ALK, Aurora A, Bmx, CDK/cyclinE, Kit, Src, EGFR, EphA1,FGFR3, Flt3, Fms, IGF-1R, IKKb, IR, Itk, JAK2, KDR, Met, mTOR, PDGFRa,Plk1, Ret, Syk, Tie2, TrtB, and so forth.

Human genome is believed to contain 518 protein kinase genes and theyconstitute about 1.7% of all human genes [Manning et al. Science, 2002,298, 1912]. Human protein kinases are largely divided intotyrosine-specific protein kinases (over 90 species) andserine/threonine-specific protein kinases. The tyrosine-specific proteinkinases may be divided into 58 receptor tyrosine kinases, which areagain grouped into 20 subfamilies, and 32 cytoplasmic/non-receptortyrosine kinases, which are grouped into 10 subfamilies. The receptortyrosine kinase has an extracellular domain capable of binding to agrowth factor and a cytoplasmic active site that can phosphorylate thetyrosine residue. When a growth factor binds to the extracellular growthfactor receptor site of the receptor tyrosine kinase, the receptortyrosine kinase forms a dimer and the tyrosine residues in the cytoplasmare autophosphorylated. Then, the downstream proteins are sequentiallyphosphorylated, and as the signal transduction proceeds in the nucleus,the transcription factors that induce cancer are overexpressed in theend.

Raf is a serine/threonine (Ser/Thr)-specific protein kinase and servesthe role of transmitting biological signals from activated growth factorreceptors on the cell membrane into the nucleus. The mitogen-activatedprotein kinase (MAPK) signal transduction system is essential incellular proliferation, division, survival, apoptosis, and the like. TheMAPK signal transduction system largely consists of three kinasephosphorylation processes—i.e., sequential phosphorylation of MAPKkinase kinase (MAPKKK), MAPK kinase (MAPKK) and MAPK. Raf is a MAPKKK,MEK is a MAPKK, and the extracellular signal-regulated kinase (ERK) is aMAPK. When the receptor is activated, the small GTP-binding protein,Ras, is activated and the MAPK signal transduction into the nucleus isperformed through sequential phosphorylation of Raf-MEK-ERK.

The Ras oncogene (especially k-Ras) in a permanently activated state isclosely related to the onset of solid tumors such as pancreatic cancer(about 90%), rectal cancer (about 45%), liver cancer (about 30%),non-small cell lung cancer (about 35%), renal cancer (about 10%), or thelike. If Raf-1 binds to activated Ras, serine 338 of Raf-1 isphosphorylated [Avruch, J. Recent Progress in Hormone Research, 2001,56, 127], and the Raf-1 is activated. In contrast, if 14-3-3 proteinbinds to Raf-1 with phosphorylated serine 259, the Raf-1 is inactivated.The Raf kinase is also involved in the nuclear factor-κB (NF-κB) signaltransduction system, which plays a key role in immune responses andinflammations [Caraglia, M. et al., Annals of Oncology, 2006, 17, 124].That is, Raf phosphorylates inactivated IκB protein and inducesmigration of NF-κB protein into the nucleus, thereby stimulating atranscription factor that inhibits apoptosis.

Another apoptosis inhibition mechanism of Raf is as follows. Raf forms adimer together with Bcl-2 and is translocated into the mitochondria.There, it phosphorylates Bad, thereby initiating apoptosis inhibition byBcl-2. Accordingly, Raf is immunoprecipitated along with Bcl-2 [Yuryev,A. et al., Mol. Cell. Biol., 2000, 20, 4870].

The three subtypes of Raf protein (A-Raf, B-Raf and C-Raf/Raf-1) havethree conserved regions (CR1, CR2 and CR3) at the N-terminal regulatorydomain and the C-terminal kinase domain. CR1 includes a Ras-bindingdomain (RBD) such as the cysteine-rich domain (CRD), CR2 includes a14-3-3 protein-binding site (e.g., serine 259 of Raf-1), and CR3includes a catalytic domain [Tran et al., J. Biol. Chem., 2005, 280,16244] and two activation segment phosphorylation sites (threonine 491and serine 494 of Raf-1) [Wellbrock, C. Nature Reviews Molecular CellBiology, 2004, 5, 875]. The three subtypes of Raf protein are expressedin different tissues. Whereas C-Raf is expressed in almost all tissues,A-Raf is mainly expressed in urogenital tissues (e.g., kidney, uterusand prostate gland) and B-Raf is mainly expressed in nervous, splenicand hematopoietic tissues [Jaiswal, R. K. et al., J. Biol. Chem., 1966,271, 23626].

Mutation of B-Raf is known to be associated with about 7% of all humancancers. Especially, it has been observed with high frequency (˜70%) inmelanoma, a type of skin cancer. Of the mutations of B-Raf, theB-Raf-V600E mutation, i.e., a point mutation with valine 600 of exon 15being replaced by glutamic acid, mainly (about 90%) induce melanoma[Davies, H. et al., Nature 2002, 417, 949]. As compared with wild-typeB-Raf, B-Raf-V600E has about 500 times higher in vitro kinase activity.Accordingly, B-Raf-V600E induces hyperactivation of the MAPK signaltransduction and leads to cancer. The reason why B-Raf-V600E has such ahigh kinase activity is as follows. The glutamic acid 600 replaced bythe point mutation mimics a phosphate group between the phosphorylationsites (threonine 598 and serine 601) located at the activation segmentand, thereby, induces structural conformation of the permanentlyactivated B-Raf kinase domain [Tuveson, D. A., Cancer Cell, 2003, 4,95]. Up to the present, about 40 B-Raf mutations were found (mainly atthe activation segment and the glycine-rich G-loop of the catalyticdomain). However, occurrence of mutations other than V600E is fairlyinfrequent. In rectal cancer, about 10% of B-Raf mutations occur at theG-loop of the catalytic domain [Rajagopalan et al., Nature 2002 418,934].

Although B-Raf has an auto-inhibition domain at the N-terminal, B-Rafbecomes permanently activated when activated H-Ras binds thereto. Thisis caused by phosphorylation of serine 445. The phosphorylation ofserine 338 of C-Raf corresponds to that of serine 445 of B-Raf. TheB-Raf V600E mutation inhibits the auto-inhibition mechanism of B-Raf andturns it permanently activated.

The B-Raf-V600E mutation is observed at high frequency (about 50%) inpapillary thyroid cancer [Salvatore, G. J. Clin. Endocrinol. Metab.2004, 89, 5175]. Also, the B-Raf-V600E is closely associated with theonset of colon cancer (about 20%) and uterine cancer (about 30%).

Also, hyperactivation of C-Raf without oncogenic mutation is observed inrenal carcinoma (about 50%) and hepatocellular carcinoma (HCC) (about100%).

Sorafenib (RAY 43-9006, marketed as Nexavar) developed by Bayer and Onyxstrongly inhibits C-Raf and both wild-type and mutant B-Raf. Further,sorafenib inhibits activity of the receptor tyrosine kinases, such asplatelet-derived growth factor receptor, vascular endothelial growthfactor receptors 1/2/3, fibroblast growth factor receptor, Flt-3, c-Kit,RET, or the like. It inhibits the kinase by stabilizing the DGF motif ofthe kinase domain to have an inactive conformation [Wan, P. T. et al.,Cell, 2004, 116, 855]. Sorafenib was approved as a treatment foradvanced renal cell carcinoma in 2005. The therapeutic effect ofsorafenib on renal cancer originates from to the inhibition of vascularendothelial growth factor receptors 1/2/3 and other kinases rather thanthe inhibition of Raf. In the clinical trial phase II, a maximum allowedadministration dose of sorafenib was 400 mg (twice a day).Administration of 600 mg (twice a day) of sorafenib may lead to grade 3skin toxicity. Frequent adverse effects of sorafenib include hand-footsyndromes such as peeling of skin, rash and edema. In 2008, sorafenibwas approved as a treatment for hepatocellular carcinoma. In addition,sorafenib showed therapeutic effect for intractable thyroid cancer,hormone-refractory prostate cancer and breast cancer in a clinical trialphase II. However, sorafenib shows no therapeutic effect on the skincancer melanoma.

PLX4720, a 7-azaindole derivative developed by Plexxikon, inducesapoptosis of melanoma cells such as 1205Lu (Raf-V660E overexpressedcells) [Tsai, J. et. al., PNAS, 2008, 105, 3041]. PLX4720 is a potentinhibitor of Raf-V660E kinase activity (IC₅₀=13 nM) and also inhibitsthe proliferation of A375 melanoma cells (IC₅₀=0.5 μM).

CHIR265 developed by Novartis and Chiron also strongly inhibits thekinase activity of B-Raf-V600E (IC₅₀=19 nM), KDR (IC₅₀=70 nM), PDGFR-b(IC₅₀=30 nM) and c-Kit (IC₅₀=20 nM). CHIR265 is currently in clinicaltrial phase I for melanoma patients.

Resistance to Raf inhibitors has been an emerging issue. Montagut et al.explained the mechanism of resistance to the Raf inhibitor by culturingM14 cells (human melanoma cells) with B-Raf-V600E mutation in thepresence of a Raf inhibitor (AZ628) and acquiring clones resistant tothe Raf inhibitor. Inhibition of B-Raf results in increased expressionof C-Raf protein and decreased inhibitory effect on B-Raf-V600E.Meanwhile, the melanoma cells resistant to the Raf inhibitor (AZ628)exhibit increased susceptibility to the HSP90 inhibitor geldanamycin.Thus, inhibition of HSP90 may be a way to overcome the resistance to theRaf inhibitor [Montagut, C. Cancer Research, 2008, 68, 4853].

Vascular endothelial growth factor receptors (VEGFRs) are receptortyrosine kinases (RTKs) and important regulatory factors ofangiogenesis. They are involved in the formation of blood vessels andlymphatic vessels and in homeostasis, and exert important effects onnerve cell. Vascular endothelial growth factor (VEGF) is produced mostlyby vascular endothelial cells, hematopoietic cells and stromal cellsunder a hypoxic condition or by stimulations from growth factors such asTGF, interleukin and PDGF. VEGF binds to VEGFR-1, -2 and -3. Each VEGFisoform binds to a specific receptor, thereby inducing the formation ofa receptor homozygote or heterozygote, and activates the correspondingsignal transduction system. The signal specificity of VEGFR is furtherfine-tuned by co-receptors such as neuropilin, heparan sulfate,integrin, cadherin, or the like.

The biological function of VEGF is mediated by type III RTK, VEGFR-1(Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (Flt-4). VEGFR is closelyrelated to Fms, Kit and PDGFR. Each VEGF binds to specific receptors.VEGF-A binds to VEGFR-1, -2 and receptor zygote, whereas VEGF-C binds toVEGF-2, -3. PIGF and VEGF-B interact exclusively with VEGFR-1, andVEGF-E interacts only with VEGFR-2. VEGF-F interacts with VEGFR-1 or -2.Whereas VEGF-A, -B and PIGF are preferentially required for theformation of blood vessels, VEGF-C and -D are essential in the formationof lymphatic vessels. Angiogenesis is essential in the proliferation andtransition of tumors, since it supplies nutrients and oxygen to thetumors and helps transition to cancer cells. Normally, angiogenesis isbalanced by angiogenic stimulators and angiogenic inhibitors. If thebalance is broken, as in cancer cells, the growth factor that affectsthe vascular endothelial cells most, i.e., VEGF, activates its receptor,VEGFR. At present, various researches are under way on the inhibitorsthat inhibit the receptor tyrosine kinase of VEGF usinglow-molecular-weight synthetic substances, which are advantageous inthat they are applicable also to solid tumors and have fewer sideeffects because they inhibit angiogenesis in cancer cells only.

Tie2 is a kind of receptor tyrosine kinase which is deeply involved withangiogenesis and vasculature. The Tie2 domain structure is highlyconserved in all vertebrates [Lyons et al., 1998]. The ligand of Tie2 isangiopoietin (Ang). Ang2 does not induce autophosphorylation of Tie2,but interferes with the activation of Tie2 by Ang1. In endothelialcells, the activation of Tie2 by Ang2 induces activation of PI3K-Akt[Jones et al., 1999]. In the mitogen-activated protein kinase (MAPK)signal transduction pathway, which is the main signal transductionsystem of Tie2, the adaptor protein GRB2 and the protein tyrosinephosphatase SHP2 play a key role in dimerization of the Tie2 receptortyrosine kinase through autophosphorylation. Ang/Tie2 and the VEGFsignal transduction pathway are important in angiogenesis of cancercells. Tie2 is expressed in vascular endothelial cells. Especially, theexpression increases remarkably at the site invaded by cancer cells.Overexpression of Tie2 was observed in breast cancer [Peters et al.,1998] and also in uterine cancer, liver cancer and brain cancer.

Several compounds with an indole structure have been synthesized.However, the indole compound of the present invention with specificsubstituents at the 1-, 3- and 6-positions of indole has never beensynthesized. Thus, of course, the inhibitory activity against variousprotein kinases or the possibility as an agent for treatment andprevention of cancers of the 1,3,6-substituted indole compound has neverbeen disclosed in any literature.

SUMMARY

The present invention relates to a novel 1,3,6-substituted indolecompound having specific substituents at the 1-, 3- and 6-positions ofindole or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition forprevention and treatment of diseases caused by abnormal cell growthincluding the novel 1,3,6-substituted indole compound or apharmaceutically acceptable thereof as an active ingredient.

In one general aspect, the present invention provides a1,3,6-substituted indole compound represented by Chemical Formula, apharmaceutically acceptable salt thereof, a hydrate thereof or a solvatethereof:

wherein

X and Y are independently selected from N or CH;

Z is selected from the group consisting of hydrogen; halogen; linear,branched or cyclic saturated or unsaturated C₁-C₆ alkyl; cyano; OR¹;—SR¹; NHR¹; —C(O)NHR¹; —NHC(O)R¹; —NHC(O)NHR¹; —S(O)R¹; and —S(O)₂R¹;

G is selected from the group consisting of halogen, 5- to 7-memberedsubstituted or unsubstituted aryl, 5- to 7-membered substituted orunsubstituted heteroaryl containing 1 to 3 heteroatom(s) selected fromnitrogen, oxygen and sulfur and a 5- to 7-membered substituted orunsubstituted heterocyclic group containing 1 to 3 heteroatom(s)selected from nitrogen, oxygen and sulfur;

L¹ is selected from the group consisting of 5- to 7-membered substitutedor unsubstituted aryl, biaryl resulting from two fused 5- to 7-memberedsubstituted or unsubstituted aryls, 5- to 7-membered substituted orunsubstituted heteroaryl containing 1 to 3 heteroatom(s) selected fromnitrogen, oxygen and sulfur and a 5- to 7-membered substituted orunsubstituted heterocyclic group containing 1 to 3 heteroatom(s)selected from nitrogen, oxygen and sulfur;

L² is nonexistent or selected from the group consisting of —NR²C(O)—,—C(O)NR²—, —NR²C(O)NR³—, —S(O)NR²— and —S(O)₂NR²—;

E is selected from the group consisting of hydrogen; linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; —NO₂; —OR³; —NR³R⁴;—NHC(O)R³; —C(O)OR³; 5- to 7-membered substituted or unsubstituted aryl;biaryl resulting from two fused 5- to 7-membered substituted orunsubstituted aryls; 5- to 7-membered substituted or unsubstitutedheteroaryl containing 1 to 3 heteroatom(s) selected from nitrogen,oxygen and sulfur; and a 5- to 7-membered substituted or unsubstitutedheterocyclic group containing 1 to 3 heteroatom(s) selected fromnitrogen, oxygen and sulfur;

R¹ is selected from the group consisting of hydrogen; linear, branchedor cyclic saturated or unsaturated C₁-C₆ alkyl; saturated or unsaturatedC₁-C₆ alkyl substituted with heteroaryl or heterocyclic ring selectedfrom the group consisting of pyrrolidinonyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl and aziridinyl;

R², R³ and R⁴ are independently selected from the group consisting ofhydrogen; and linear, branched or cyclic saturated or unsaturated C₁-C₆alkyl;

wherein the above aryl, heteroaryl, biaryl or heterocyclic isindependently substituted or unsubstituted with 1 to 3 substituent(s)selected from the group consisting of hydrogen; halogen; linear,branched or cyclic saturated or unsaturated C₁-C₆ alkyl; C₁-C₆ haloalkylcontaining 1 to 10 halogen atoms; cyano; —NO₂; —OBoc; —OR⁵;—O(CH₂)_(n)NR⁶R⁷ (where n is an integer from 1 to 6); —NR⁶R⁷; —NR⁵COR⁶;—NR⁵C(O)NR⁶R⁷; —C(O)R⁶; —C(O)OR⁶; —C(O)NR⁶R⁷; —C(O)NH(CH₂)_(n)NR⁶R⁷;—S(O)R⁶; —S(O)₂R⁶; —S(O)₂NR⁶R⁷, 5- to 7-membered aryl, biaryl resultingfrom two fused 5- to 7-membered aryls; 5- to 7-membered heteroarylcontaining 1 to 3 heteroatom(s) selected from nitrogen, oxygen andsulfur; and a 5- to 7-membered heterocyclic ring containing 1 to 3heteroatom(s) selected from nitrogen, oxygen and sulfur; and

R⁵, R⁶ and R⁷ are independently selected from the group consisting ofhydrogen; halogen; linear, branched or cyclic saturated or unsaturatedC₁-C₆ alkyl; 5- to 7-membered aryl; biaryl resulting from two fused 5-to 7-membered aryls; 5- to 7-membered heteroaryl containing 1 to 3heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5- to7-membered heterocyclic ring containing 1 to 3 heteroatom(s) selectedfrom nitrogen, oxygen and sulfur; or NR⁶R⁷ forms 5- to 7-memberedheteroaryl or a heterocyclic ring by further including 1 to 3 otherheteroatom(s), wherein the aryl, biaryl, heteroaryl or heterocyclic ringmay be substituted with 1 to 3 substituent(s) selected from the groupconsisting of halogen, C₁-C₆ alkyl and C₁-C₆ haloalkyl containing 1 to10 halogen atoms.

The 1,3,6-substituted indole compound represented by Chemical Formula 1,a pharmaceutically acceptable salt thereof, a hydrate thereof or asolvate thereof has superior capability of inhibiting the activity ofprotein kinases selected from Raf, KDR, Fms, Tie2, SAPK2a, Ret, Abl,Abl(T315I), ALK, Aurora A, Bmx, CDK/cyclinE, Kit, Src, EGFR, EphA1,FGFR3, Flt3, Fms, IGF-IR, IKKb, IR, Itk, JAK2, KDR, Met, mTOR, PDGFRa,Plk1, Ret, Syk, Tie2 and TrtB, and thus is effective for preventing andtreating diseases caused by abnormal cell growth.

The diseases caused by abnormal cell growth that may be prevented ortreated by the compound according to the present invention may includevarious cancers selected from stomach cancer, lung cancer, liver cancer,colorectal cancer, small intestine cancer, pancreatic cancer, braincancer, bone cancer, melanoma, breast cancer, sclerosing adenoma,uterine cancer, cervical cancer, head and neck cancer, esophagealcancer, thyroid cancer, parathyroid cancer, renal cancer, sarcoma,prostate cancer, urethral cancer, bladder cancer, leukemia, multiplemyeloma, hematological malignancy such as myelodysplastic syndrome,lymphoma such as Hodgkin's disease and non-Hodgkin lymphoma,fibroadenoma, or the like.

Other features and aspects will be apparent from the following detaileddescription, the drawings, and the claims.

BRIEF DESCRIPTION OF THE DRAWING

The above and other objects, features and advantages of the presentinvention will become apparent from the following description ofpreferred embodiments given in conjunction with the accompanyingdrawing, in which:

FIG. 1 shows an inhibitory activity of1-(2-methoxyphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea(compound of Example 39) for B-Raf-V600E kinase.

DETAILED DESCRIPTION OF EMBODIMENTS

The advantages, features and aspects of the present invention willbecome apparent from the following description of the embodiments withreference to the accompanying drawings, which is set forth hereinafter.The present invention may, however, be embodied in different forms andshould not be construed as limited to the embodiments set forth herein.Rather, these embodiments are provided so that this disclosure will bethorough and complete, and will fully convey the scope of the presentinvention to those skilled in the art. The terminology used herein isfor the purpose of describing particular embodiments only and is notintended to be limiting of example embodiments. As used herein, thesingular forms “a”, an and “the” are intended to include the pluralforms as well, unless the context clearly indicates otherwise. It willbe further understood that the terms “comprises” and/or “comprising”,when used in this specification, specify the presence of statedfeatures, integers, steps, operations, elements, and/or components, butdo not preclude the presence or addition of one or more other features,integers, steps, operations, elements, components, and/or groupsthereof.

Hereinafter, exemplary embodiments will be described in detail withreference to the accompanying drawing.

A pharmaceutically acceptable salt of the 1,3,6-substituted indolecompound represented by Chemical Formula 1 may be prepared by a methodcommonly employed in the art. A pharmaceutically acceptable salt shouldbe less toxic to the human body and should not have negative effects onthe biological activity and physical and chemical properties of themother compound. The pharmaceutically acceptable salt includes a freeacid, an acid addition salt of a base compound represented by ChemicalFormula 1, an alkali metal salt (e.g., a sodium salt), an alkaline earthmetal salt (e.g., a calcium salt), an organic salt, an organic baseaddition salt of a carboxylic acid represented by Chemical Formula 1,and an amino acid addition salt. The free acid that may be used toprepare the pharmaceutically acceptable salt includes an inorganic acidor an organic acid. The inorganic acid may be hydrochloric acid,sulfuric acid, nitric acid, phosphoric acid, perchloric acid, bromicacid, or the like. The organic acid may be acetic acid, methanesulfonicacid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleicacid, malonic acid, phthalic acid, succinic acid, lactic acid, citricacid, gluconic acid, tartaric acid, salicylic acid, malic acid, oxalicacid, benzoic acid, embonic acid, aspartic acid, glutamic acid, or thelike. The organic base that may be used to prepare the organic baseaddition salt includes tris(hydroxymethyl)methylamine,dicyclohexylamine, or the like. The amino acid that may be used toprepare the amino acid addition salt includes a naturally occurringamino acid such as alanine, glycine, or the like.

The 1,3,6-substituted indole compound represented by Chemical Formula 1includes, in addition to the pharmaceutically acceptable salts, allhydrates and solvates. The hydrate or the solvate may be prepared bydissolving the 1,3,6-substituted indole compound represented by ChemicalFormula 1 in a water-miscible solvent such as methanol, ethanol, acetoneand 1,4-dioxane, adding a free acid or a free base thereto, and thenperforming crystallization or recrystallization. In that case, a solvate(particularly a hydrate) may be formed. Accordingly, the compound of thepresent invention includes, in addition to the compounds containingvarious amounts of water that can be prepared through, for example,lyophilization, stoichiometric solvates including hydrates.

Hereunder is given a detailed description about the substituents used todefine the compound according to the present invention.

In the present invention, ‘halogen’ means a fluorine, chlorine, bromineor iodine atom.

In the present invention, ‘alkyl’ means a C₁-C₆ aliphatic saturatedhydrocarbon group, including methyl, ethyl, n-propyl, i-propyl,cyclopropyl, n-butyl, i-butyl, t-butyl, cyclobutyl, cyclopropylmethyl,n-pentyl, i-pentyl, neopentyl, t-pentyl, cyclopentyl, cyclobutylmethyl,n-hexyl, i-hexyl, cyclohexyl, cyclopentylmethyl, heptyl,cyclohexylmethyl, octyl, or the like.

In the present invention, ‘haloalkyl’ means an alkyl group with one ormore hydrogen(s) substituted by halogen atom(s), such astrifluoromethyl.

In the present invention, ‘alkoxy’ means a hydroxyl group with thehydrogen substituted by C₁-C₆ alkyl group including methoxy, ethoxy,n-propoxy, i-propoxy, n-butoxy, i-butoxy and t-butoxy.

In the present invention, ‘aryl’ means a mono-, bi- or tricyclicaromatic hydrocarbon group, such as phenyl, naphthyl, anthracenyl,phenanthrenyl, or the like.

In the present invention, ‘biaryl’ means an aromatic hydrocarbon groupformed from two fused aryl groups, such as biphenyl, phenoxyphenyl,benzoylphenyl, phenyldiazenylphenyl, or the like.

In the present invention, ‘heteroaryl’ means a mono-, bi- or tricyclicaromatic heterohydrocarbon group containing one or more heteroatom(s),such as pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl,isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl,thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyridazinyl,pyrimidinyl, triazolyl, indolyl, isoindolyl, benzofuranyl,benzofurazanyl, dibenzofuranyl, isobenzofuranyl, indazolyl,benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl,dibenzothiophenyl, naphthyridyl, benzisothiazolyl, quinolinyl,isoquinolinyl, quinoxalinyl, phthalazinyl, cinnolinyl, quinazolinyl, orthe like.

In the present invention, ‘heterocyclic ring’ means a heterohydrocarbonring containing one or more heteroatom(s), such as morpholinyl,piperidinyl, piperazinyl, N-protected piperazinyl, or the like.

Preferably, in the 1,3,6-substituted indole compound represented byChemical Formula 1, X and Y are independently selected from N or CH; Zis selected from the group consisting of hydrogen, halogen, —SR¹, NHR¹and —S(O)R¹; G is selected from the group consisting of halogen,indolyl.

and substituted or unsubstituted aryl; L¹ is selected from the groupconsisting of substituted or unsubstituted aryl, and a substituted orunsubstituted heterocyclic ring containing 1 to 3 heteroatom(s) selectedfrom nitrogen, oxygen and sulfur; L² is nonexistent or selected from thegroup consisting of —NR²C(O)— and —NR²C(O)NR³—; E is selected from thegroup consisting of hydrogen, linear-, branched- or cyclic saturated orunsaturated C₁-C₆ alkyl, —NO₂, —OR³, —NR³R⁴, —NHC(O)R³ and substitutedor unsubstituted aryl; R¹, R², R³ and R⁴ are independently selected fromthe group consisting of hydrogen, linear-, branched- or cyclic saturatedor unsaturated C₁-C₆ alkyl and substituted or unsubstituted aryl; thesubstituted aryl or heterocyclic ring is independently aryl or aheterocyclic ring substituted with 1 to 3 substituent(s) selected fromthe group consisting of halogen, linear, branched or cyclic saturated orunsaturated C₁-C₆ alkyl, C₁-C₆ haloalkyl containing 1 to 10 halogenatoms, cyano, —NO₂, —OBoc, —OR⁵, —O(CH₂)_(n)NR⁶R⁷ (where n is an integerfrom 1 to 6), —NR⁶R⁷, —NR⁵COR⁶, —NR⁵C(O)NR⁶R⁷, —C(O)R⁶, —C(O)OR⁶,—C(O)NR⁶R⁷, —C(O)NH(CH₂)_(n)NR⁶R⁷, substituted or unsubstituted aryl anda heterocyclic ring containing 1 to 3 heteroatom(s) selected fromnitrogen, oxygen and sulfur; R⁵, R⁶ and R⁷ are independently selectedfrom the group consisting of hydrogen, halogen, linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl and substituted orunsubstituted aryl, or NR⁶R⁷ forms a heterocyclic ring by optionallyfurther including 1 to 3 other heteroatom(s), wherein the aryl orheterocyclic ring may be substituted with 1 to 3 substituent(s) selectedfrom the group consisting of halogen, C₁-C₆ alkyl and C₁-C₆ haloalkylcontaining 1 to 10 halogen atoms; the aryl is phenyl; and theheterocyclic ring is selected from the group consisting of morpholinyl,piperidinyl, piperazinyl and N-protected piperazinyl.

More preferably, in the 1,3,6-substituted indole compound represented byChemical Formula 1, X and Y are independently N or CH; Z is hydrogen,Cl, —SCH₃, NH₂, NHCH₃, NH-cyclopropyl, NHCH₂CH₂-morpholinyl or —S(O)CH₃;G is Br, indolyl or substituted or unsubstituted phenyl; L¹ issubstituted or unsubstituted phenyl, piperazinyl or N-Boc-piperazinyl;L² is nonexistent or —NHC(O)— or —NHC(O)NH—; E is hydrogen, cyclohexyl,—NO₂, —OH, —OCH₃, —NH₂, —NHC(O)CH₃ or substituted or unsubstitutedphenyl; and the substituted phenyl is phenyl substituted with 1 to 3substituent(s) selected from the group consisting of —Cl, —F, —CH₃,—CF₃, —CN, —NO₂, —OH, —OBoc, —OCH₃, —OCH₂CH₂N(CH₃)₂, —NH₂, —NHC(O)CH₃,—NHC(O)Ph, —NHC(O)-Ph(4-Cl,3-CF₃), NHSO₂-cyclopropyl, —C(O)OH,—C(O)OCH₂CH₃, —C(O)NH-cyclopropyl, —C(O)NHCH₂CH₂-morpholinyl,morpholinyl, 4-ethylpiperazinyl and 4-methylimidazolyl.

Specific examples of the 1,3,6-substituted indole compound representedby Chemical Formula 1 include:

-   tert-butyl    4-(3-bromo-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate;-   4-(3-bromo-1-(pyridin-4-yl)-1H-indol-6-yl)phenol;-   3-bromo-6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indole;-   3-bromo-1-(2-(methylthio)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole;-   3-bromo-1-(6-chloropyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole;-   6-(3-bromo-6-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine;-   3-bromo-1-(6-chloropyrimidin-4-yl)-6-(4-methoxyphenyl)-1H-indole;-   6-(3-bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine;-   tert-butyl 4-(3-(4-methoxyphenyl)-1-(pyridin    4-yl)-1H-indol-6-yl)piperazine-1-carboxylate;-   3-(4-methoxyphenyl)-6-(piperazin-1-yl)-1-(pyridin-4-yl)-1H-indole;-   4-(6-(piperazin-1-yl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenol;-   tert-butyl    4-(3-(4-(tert-butoxycarbonyloxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate;-   tert-butyl    4-(3-(4-hydroxyphenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate;-   tert-butyl    4-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate;-   N,N-dimethyl-2-(4-(6-(piperazin-1-yl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenoxy)ethanamine;-   3-(4-methoxyphenyl)-6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indole;-   4-(6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indol-1-yl)phenol;-   4-(6-(3-aminophenyl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenol;-   N,N-dimethyl-2-(4-(6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-Indol-3-yl)phenoxy)ethanamine;-   3-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)benzenamine;-   N-(3-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)phenyl)acetamide;-   6-(6-(4-methoxyphenyl)-3-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine;-   6-(3-(1-aminophenyl)-6-(4-methoxyphenyl)-1H-Indol-1-yl)-N-methylpyrimidin-4-amine;-   N-(3-(6-(4-ethoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)acetamide;-   ethyl    4-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzoate;-   4-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzoate;-   4-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)-N-(2-morpholinoethyl)benzamide;-   3-(4-methoxyphenyl)-1-(2-(methylthio)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole;-   3-(4-methoxyphenyl)-1-(2-(methylsulfinyl)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole;-   4-(3-(4-methoxyphenyl)-6-(3-nitrophenyl)-1H-indol-1-yl)pyrimidin-2-amine;-   6-(3-(4-methoxyphenyl)-6-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine;-   6-(6-(3-aminophenyl)-3-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine;-   1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea;-   1-(3,4-dichlorophenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea;-   1-(2-methoxyphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea;-   1-(2-fluorophenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea;-   1-cyclohexyl-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea;-   N-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)-4-methyl-3-nitrobenzamide;-   N-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)-3-morpholino-5-(trifluoromethyl)benzamide;-   N-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide;-   1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)urea;-   4-chloro-N-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)-3-(trifluoromethyl)benzamide;-   N-cyclopropyl-4-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzamide;-   1-(2,6-dimethylphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indo)-6-yl)phenyl)urea;-   1-(4-(4-ethylpiperazin-1-yl)-2-methoxyphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methyl    amino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea;-   1-(5-chloro-2,4-dimethoxyphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea;-   N-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)cyclopropanecarboxamide;-   N-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)cyclopropanesulfonamide;-   6-(6-(4-methoxyphenyl)-1H,    1′H-3,6′-biindol-1-yl)-N-methylpyrimidin-4-amine;-   6-(6-(4-methoxyphenyl)-3-(4-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine;-   6-(3-(4-aminophenyl)-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine;-   6-(3-bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-(2-morpholinoethyl)pyrimidin-4-amine;-   6-(3-bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-cyclopropylpyrimidin-4-amine;-   6-(6-(4-methoxyphenyl)-3-(3-nitrophenyl)-1H-indol-1-yl)-N-(2-morpholinoethyl)pyrimidin-4-amine;-   N-cyclopropyl-6-(6-(4-methoxyphenyl)-3-(3-nitrophenyl)-1H-indol-1-yl)pyrimidin-4-amine;-   6-(3-(3-aminophenyl)-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-(2-morpholinoethyl)pyrimidin-4-amine;-   6-(3-(3-aminophenyl)-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-cyclopropylpyrimidin-4-amine;    and-   ethyl    4-(6-(4-methoxyphenyl)-1-(6-(2-morpholinoethylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzoate.

The present invention also provides a method for preparing the indolecompound represented by Chemical Formula 1. A typical example is asfollows.

According to Scheme 1, a Suzuki coupling reaction of a bromine compoundrepresented by Chemical Formula 2 with a boronic acid compoundrepresented by Chemical Formula 3 is performed using an organometalliccompound to prepare the 3,6-substituted indole compound represented byChemical Formula 1.

In Scheme 1, X, Y, Z, L₁, L₂, E and G are the same as defined above.

Schemes 2 to 4 exemplify introduction of various substituents to the1,3,6-substituted indole compound represented by Chemical Formula 1.

According to Scheme 2, various OR² groups are introduced to thesubstituent G at the C-3 position of indole. It is performed by a twostep process. First, a methoxy compound represented by Chemical Formula1a is deprotected to prepare an alcohol compound represented by ChemicalFormula 1b (Step 2-1). Then, the alcohol compound represented byChemical Formula 1b is reacted with a compound represented by ChemicalFormula 10 under a basic condition to prepare an OR⁵-substitutedcompound represented by Chemical Formula 1c (Step 2-2).

In Scheme 2, X, Y, Z, L₁, L₂, E and G are the same as defined above, Ris halogen or a leaving group, and the base is sodium tert-butoxide,sodium hydride, or the like.

According to Scheme 3, various amide groups represented by —CONR⁶R⁷ areintroduced to the substituent G at the C-3 position of indole. It isperformed by a two step process. First, a carboxylate ester compoundrepresented by Chemical Formula id is hydrolyzed to prepare a carboxylicacid compound represented by Chemical Formula 1e (Step 3-1). Then, thecarboxylic acid compound represented by Chemical Formula 1e is coupledwith an amine compound represented by Chemical Formula 1l to prepare anamide compound represented by Chemical Formula 1f (Step 3-2).

In Scheme 3, X, Y, Z, L₁, L₂, E, G, R⁶ and R⁷ are the same as definedabove.

According to Scheme 4, various amide groups represented by —NR⁵COR⁶ areintroduced to the substituent G at the C-3 position of indole. It isperformed by a two step process. First, a nitro compound represented byChemical Formula 1g is reduced to prepare an amine compound representedby Chemical Formula 1h (Step 4-1). Then, the amine compound representedby Chemical Formula 1h is coupled with an acyl compound represented byChemical Formula 12 to prepare an amide compound represented by ChemicalFormula 1i (Step 4-2).

In Scheme 4, X, Y, Z, L₁, L₂, E, G, R⁵ and R⁶ are the same as definedabove, and R is halogen or a leaving group.

According to Scheme 5, various -L²-E groups are introduced to thesubstituent L¹ at the C-6 position of indole. It is performed by a twostep process. First, a nitro compound represented by Chemical Formula 1jis reduced to prepare an amine compound represented by Chemical Formula1k (Step 5-1). Then, the amine compound represented by Chemical Formula1k is coupled with an isocyanate compound represented by ChemicalFormula 13 or a carboxylic acid compound represented by Chemical Formula14 to prepare a compound represented by Chemical Formula 1 (Step 5-2).

In Scheme 5, X, Y, Z, L₁, L₂, E and G are the same as defined above.

The compound represented by Chemical Formula 2, which is used as astarting material in Scheme 1, may be prepared by Scheme 6 or 7.

According to Scheme 6, a 6-bromoindole compound represented by ChemicalFormula 3 is Suzuki-coupled using an organometallic compound to preparea 6-substituted indole compound represented by Chemical Formula 4 (Step6-1). Then, the 6-substituted indole compound represented by ChemicalFormula 4 is coupled with a compound represented by Chemical Formula 8using a metal comprising palladium to prepare a compound represented byChemical Formula 5a (Step 6-2). Then, the compound represented byChemical Formula 5a is brominated to prepare the bromine compoundrepresented by Chemical Formula 2 (Step 6-3).

In Scheme 6, X, Y, Z, L₁, L₂ and E are the same as defined above, R ishalogen or a leaving group, and the base is sodium tert-butoxide, sodiumhydride, or the like.

According to Scheme 7, a 6-bromoindole compound represented by ChemicalFormula 3 is Suzuki-coupled using an organometallic compound to preparea 6-substituted indole compound represented by Chemical Formula 4 (Step7-1). Then, the 6-substituted indole compound represented by ChemicalFormula 4 is brominated to prepare a compound represented by ChemicalFormula 5b (Step 7-2). Then, the compound represented by ChemicalFormula 5b is coupled with a compound represented by Chemical Formula 8using a base to prepare the bromine compound represented by ChemicalFormula 2 (Step 7-3).

In Scheme 7, X, Y, Z, L₁, L₂ and E are the same as defined above, R ishalogen or a leaving group, and the base is sodium tert-butoxide, sodiumhydride, or the like.

The 1,3,6-substituted indole compound represented by Chemical Formula 1,a pharmaceutically acceptable salt thereof, a solvate thereof and ahydrate thereof may be used as an agent for preventing or treatingdiseases caused by abnormal cell growth because they exhibit superiorinhibitory activity for various protein kinases, e.g., Raf, KDR, Fms,Tie2, SAPK2a, Ret, Abl, Abl(T315I), ALK, Aurora A, Bmx, CDK/cyclinE,Kit, Src, EGFR, EphA1, FGFR3, Flt3, Fms, IGF-1R, IKKb, IR, Itk, JAK2,KDR, Met, mTOR, PDGFRa, Plk1, Ret, Syk, Tie2 and TrtB. Examples of thediseases caused by abnormal cell growth include various cancers such asstomach cancer, lung cancer, liver cancer, colorectal cancer, smallintestine cancer, pancreatic cancer, brain cancer, bone cancer,melanoma, breast cancer, sclerosing adenoma, uterine cancer, cervicalcancer, head and neck cancer, esophageal cancer, thyroid cancer,parathyroid cancer, renal cancer, sarcoma, prostate cancer, urethralcancer, bladder cancer, leukemia, multiple myeloma, hematologicalmalignancy such as myelodysplastic syndrome, lymphoma such as Hodgkin'sdisease and non-Hodgkin lymphoma, fibroadenoma, or the like.

Accordingly, the present invention provides a pharmaceutical compositioncomprising the indole compound represented by Chemical Formula 1, apharmaceutically acceptable salt thereof, a solvate thereof or a hydratethereof as an active ingredient, and an agent for preventing andtreating various cancers caused by abnormal cell growth.

The pharmaceutical composition of the present invention comprises theindole compound represented by Chemical Formula 1, a pharmaceuticallyacceptable salt thereof, a solvate thereof or a hydrate thereof as anactive ingredient and may further include a commonly used, nontoxic,pharmaceutically acceptable carrier, adjuvant, excipient, or the like toprepare formulations commonly used in the pharmaceutical field, forexample, formulations for oral administration such as tablet, capsule,troche, liquid, suspension, etc. and formulations for parenteraladministration.

The excipient that may be used in the pharmaceutical composition of thepresent invention includes a sweetener, a binder, a solubilizer, awetting agent, an emulsifier, an isotonic agent, an adsorbent, adisintegrant, an antioxidant, a preservative, a lubricant, a filler, anaromatic, or the like. For example, lactose, dextrose, sucrose,mannitol, sorbitol, cellulose, glycine, silica, talc, stearic acid,stearin, magnesium stearate, magnesium aluminum silicate, starch,gelatin, gum tragacanth, alginic acid, sodium alginate, methylcellulose,sodium carboxymethylcellulose, agar, water, ethanol, polyethyleneglycol, polyvinylpyrrolidone, sodium chloride, calcium chloride, orangeessence, strawberry essence, vanilla flavor, or the like may be used.

The administration dose of the compound according to the presentinvention may vary depending on the patient's age, body weight, sex andphysical conditions, administration type, severity of disease, etc.Based on an adult patient weighing 70 kg, the administration dose may bein general 0.01 to 1,000 mg/day. As per the decision by a physician or apharmacist, the administration may be made once or several times a daywith predetermined time intervals.

PREPARATION EXAMPLES

The preparation examples will now be described. The following examplesare for illustrative purposes only and not intended to limit the scopeof this disclosure.

Preparation Example 1 6-bromo-1H-indole

To a mixture solution of 4-bromo-2-nitrotoluene (2.00 g, 9.26 mmol) anddimethylformamide-dimethylacetal (3.68 mL, 27.8 mmol) in DMF (20 mL),pyrrolidine (1.16 mL, 13.9 mmol) was added at room temperature. Afterstirring at 110° C. for an hour, the mixture was cooled to roomtemperature and then water was added. After extracting 3 times withether, the collected organic layer was dried with anhydrous magnesiumsulfate and the concentrated. The resulting residue was subjected to thenext reaction without purification. After adding 80% acetic acid aqueoussolution (60 mL), the mixture was heated to 85° C. While adding zincpowder (5.27 g, 80.6 mmol) in small amounts, the mixture was stirred at85° C. for 2 hours. After cooling to room temperature and filtering,followed by addition of water, the filtrate was extracted with ethylacetate. The collected organic layer was washed with brine andconcentrated by drying with anhydrous magnesium sulfate. The residue waspurified by chromatography (silica gel, EA:Hx=1:20). The target compound(710 mg) was obtained as violet solid.

¹H NMR (400 MHz, DMSO-d₆) δ 11.21 (br, 1H), 7.56 (s, 1H), 7.49 (d, 1H),7.36 (m, 1H), 7.10 (d, 1H), 6.44 (m, 1H).

Preparation Example 2 tert-butyl4-(1H-indol-6-yl)piperazine-1-carboxylate

Pd₂(dba)₃ (30 mg, 0.026 mmol), tert-butyl piperazine-1-carboxylate (570mg, 3.06 mmol), X-Phos (CAS Number: 564483-18-7, 40 mg, 0.077 mmol) and6-bromo-1H-indole (500 mg, 2.55 mmol) were added to THF (2 mL) in asealed reactor. After adding lithium hexamethyldisilazide (LHMDS; 1 M inTHF, 5.61 mL, 5.6 mmol) at room temperature, the mixture solution wasstirred at 65° C. for 24 hours in a sealed state. After cooling to roomtemperature, the reaction was terminated with saturated ammoniumchloride aqueous solution. After extraction with ethyl acetate, thecollected organic layer was washed with saturated sodium bicarbonateaqueous solution and brine and then concentrated by drying withanhydrous sodium sulfate. The residue was purified by chromatography(silica gel, EA:Hx=1:2). The target compound (334 mg) was obtained aswhite solid.

¹H NMR (400 MHz, DMSO-d₆) δ 10.79 (s, 1 H), 7.38 (d, J=8.8 Hz, 1 H),7.15 (br s, 1 H), 6.85 (s, 1 H), 6.78 (d, J=8.8 Hz, 1 H), 6.28 (s, 1 H),3.48 (t, J=4 Hz, 4 H), 3.01 (t, J=4 Hz, 4 H), 1.43 (s, 9 H).

Preparation Example 3 6-(4-methoxyphenyl)-1H-indole

6-Bromo-1H-indole (1.00 g, 5.10 mmol) and potassium carbonate (1.41 g,10.2 mmol) were dissolved in a mixture solution of DMF/water (4:1, 10.0mL), and the gas included in the mixture solution was removed usingultrasonic waves and nitrogen gas. After sequentially adding4-methoxyphenylboronic acid (853 mg, 5.61 mmol) and Pd(dppf)Cl₂ (416 mg,0.51 mmol), the mixture was stirred at room temperature

in a sealed state. 2 hours later, ethyl acetate and water were added andthe reaction solution was filtered using a diatomite pad. Afterseparation of the organic layer, the aqueous layer was extracted withethyl acetate. The collected organic layer was concentrated by dryingwith anhydrous magnesium sulfate. The residue was purified bychromatography (silica gel, EA:Hx=1:4). The target compound was obtainedas white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.19 (br, 1H), 7.68 (d, 1H), 7.59 (d, 2H),7.56 (s, 1H), 7.35 (m, 1H), 7.25 (m, 1H), 7.00 (d, 2H), 6.57 (m, 1H),3.87 (s, 3H); MS m/z [M+1] 224.20.

Preparation Example 4 4-(1H-indol-6-yl)phenol

The target compound was prepared as in Preparation Example 3 usingsuitable starting materials.

¹H NMR (400 MHz, DMSO-d₆) δ 11.07 (s, 1 H), 9.41 (s, 1 H), 7.56 (d,J=10.4 Hz, 1 H), 7.53 (s, 1 H), 7.48 (d, J=12 Hz, 1 H), 7.47 (d, J=11.6Hz, 2 H), 7.20 (d, J=6.8 Hz, 1 H), 6.84 (d, J=11.6 hz, 2 H), 6.40 (s, 1H).

Preparation Example 5 6-(3-nitrophenyl)-1H-indole

The target compound was prepared as in Preparation Example 3 usingsuitable starting materials.

¹H NMR (400 MHz, CDCl₃) δ 8.52 (m, 1H), 8.32 (br, 1H), 8.17 (dd, 1H),7.98 (d, 1H), 7.76 (d, 1H), 7.71 (s, 1H), 7.60 (t, 1H), 7.41 (dd, 1H),7.31 (m, 1H), 6.63 (m, 1H); MS m/z [M+1] 239.18.

Preparation Example 6 4-(3-bromo-1H-indol-6-yl)phenol

A mixture solution of bromine (25 μL, 0.48 mmol) in DMF (1 mL) was addedto a mixture solution of 4-(1H-indol-6-yl)phenol (100 mg, 0.48 mmol) inDMF (1 mL) at room temperature. After stirring for 1.5 hours at roomtemperature, followed by addition of icy water and addition of sodiumthiosulfate, the mixture was stirred for 1 hour. Thus produced solid wasfiltered, washed with water and dried at room temperature. The targetcompound (136 mg) was obtained as white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 11.45 (s, 1H), 9.47 (s, 1H), 7.53 (m, 1H),7.52 (s, 1H), 7.47 (d, 2H), 7.41 (d, 1H), 7.33 (d, 1H), 6.84 (d, 2H); MSm/z [M+1] 287.17, 289.10.

Preparation Example 7 3-bromo-6-(3-nitrophenyl)-1H-indole

The target compound was prepared as in Preparation Example 6 usingsuitable starting materials.

¹H NMR (400 MHz, CDCl₃) δ 8.51 (s, 1H), 8.38 (hr 1H), 8.19 (d, 1H), 7.96(d, 1H), 7.69 (d, 1H), 7.64 (s, 1H), 7.60 (d, 1H), 7.48 (d, 1H), 7.32(d, 1H); MS m/z [M+1] 316.15, 318.10.

Preparation Example 8 3-bromo-6-(4-methoxyphenyl)-1H-indole

The target compound was prepared as in Preparation Example 6 using6-(4-methoxyphenyl)-1H-indole (500 mg, 2.24 mmol) and bromine (115 μL,2.24 mmol).

¹H NMR (400 MHz, CDCl₃) δ 8.21 (br, 1H), 7.61 (d, 1H), 7.57 (d, 2H),7.53 (s, 1H), 7.43 (d, 1H), 7.24 (d, 1H), 7.00 (d, 2H), 3.87 (s, 3H); MSm/z [M+1] 301.01, 303.08.

EXAMPLES

The following examples exemplify the preparation of the compoundrepresented by Chemical Formula 1 or a pharmaceutically acceptablethereof. However, the present invention is not limited thereto.

Example 1 tert-butyl4-(1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate

tert-Butyl 4-(1H-indol-6-yl)piperazine-1-carboxylate (500 mg, 1.66mmol), sodium tert-butoxide (447 mg, 4.65 mmol), 4-bromopyridinehydrochloride (355 mg, 1.83 mmol) and toluene (11 mL) were sequentiallyacted to a reactor. Then, the gas dissolved in the mixture was removedusing ultrasonic waves and nitrogen gas. After adding 10% (w/w)palladium-carbon (Pd—C, 177 mg, 0.083 mmol) and2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP; 52 mg, 0.083 mmol),the mixture was stirred at 100° C. for 24 hours in a sealed state. Aftercooling to room temperature and filtering using a diatomite pad, waterwas added and the mixture was extracted with ethyl acetate. Thecollected organic layer was washed with brine and concentrated underreduced pressure by drying with anhydrous sodium sulfate. The residuewas purified by chromatography (silica gel, EA:Hx=1:1→EA only). Thetarget compound (369 mg, 59%) was obtained as white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.68 (d, J=6 Hz, 2 H), 7.69 (d, J=6 Hz, 2H), 7.64 (d, J=3.2 hz, 1 H), 7.52 (d, J=8.4 Hz, 1 H), 7.36 (d, J=4.8 Hz,1 H), 7.33 (dd, J=2, 11.2 Hz, 1 H), 6.73 (d, J=4.8 Hz, 1 H).

Example 2 tert-butyl4-(3-bromo-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate

N-Bromosuccinimide (64.4 mg, 0.36 mmol) was added to a mixture solutionof tert-butyl 4-(1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate(137 mg, 0.36 mmol) in THF (12 mL) at −78° C. After stirring at −78° C.for 2 hours, the mixture was further stirred at 0° C. for 1 hour andthen pyridine (88 μL, 1.09 mmol) was added. After filtering using adiatomite pad, the solution was adsorbed by adding silica gel.Purification by chromatography (silica gel, EA:Hx=4:1) yielded thetarget compound (49.1 mg, 30%) as white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.82 (d, J=6 Hz, 2 H), 7.57 (d, J=6 Hz, 2H), 7.46 (d, J=8.8 Hz, 1 H), 6.95 (dd, J=2, 8.8 Hz, 1 H), 6.83 (s, 1 H),6.66 (s, 1 H), 3.39 (br s, 4 H), 3.01 (br s, 4 H), 1.39 (s, 9 H).

Example 3 4-(1-(pyridin-4-yl)-1H-indol-6-yl)phenol

The target compound was prepared as in Example 1 using4-(1H-indol-6-yl)phenol (200 mg, 0.96 mmol) and 4-bromopyridinehydrochloride (205 mg, 1.06 mmol).

¹H NMR (400 MHz, DMSO-d₆) δ 9.49 (s, 1 H), 8.71 (d, J=4.8 Hz, 2 H), 7.87(s, 1 H), 7.82 (d, J=3.6 Hz, 2 H), 7.77 (d, J=4.8 Hz, 2 H), 7.70 (d, J=8Hz, 1 H), 7.54 (d, J=8.4 Hz, 2H), 7.41 (br d, J=8 Hz, 1 H), 6.85 (d, J=8Hz, 2 H), 6.80 (d, J=3.2 Hz, 1 H).

Example 4 4-(3-bromo-1-(pyridin-4-yl)-1H-indol-6-yl)phenol

N-Bromosuccinimide (8.1 mg, 0.046 mmol) was added to a mixture solutionof tert-butyl 4-(1-(pyridin-4-yl)-1H-indol-6-yl)phenol (10 mg, 0.035mmol) in THF (0.5 mL) mixture solution at −78° C. After stirring at −78°C. for 2 hours, the mixture was further stirred at 0° C. for 1 hour andthen pyridine (8.5 μL, 0.105 mmol) was added. After stirring at roomtemperature for 30 minutes, water was added and the mixture wasextracted with ethyl acetate. The collected organic layer was washedwith saturated sodium bicarbonate solution and brine, and thenconcentrated under reduced pressure by drying with anhydrous magnesiumsulfate. The target compound was obtained as white solid.

MS m/z [M+1] 365.11, 367.13.

Example 5 1-(2-(methylthio)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole

Sodium hydride (60% in mineral oil, 40 mg, 0.98 mmol) was added to amixture solution of 6-(3-nitrophenyl)-1H-indole (117 mg, 0.49 mmol) inDMF (2 mL) at room temperature. 10 minutes later,4-chloro-2-(methylthio)pyrimidine (68 μL, 0.59 mmol) was added. Afterstirring at room temperature for 30 minutes, water was added. Thusproduced solid was filtered and dried. The target compound (102 mg) wasobtained as white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.95 (m, 1H), 8.56 (m, 1H), 8.53 (d, 1H), 8.21(d, 1H), 8.01 (d, 1H), 7.76 (s, 1H), 7.74 (d, 1H), 7.65 (t, 1H), 7.54(dd, 1H), 7.07 (d, 1H), 6.83 (d, 1H), 2.73 (s, 3H); MS m/z [M+1] 363.22.

Example 6 6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indole

The target compound was prepared as in Example 1 using6-(3-nitrophenyl)-1H-indole (98 mg, 0.412 mmol) and 4-bromopyridinehydrochloride (88 mg, 0.453 mmol).

¹H NMR (400 MHz, DMSO-d₆) δ 8.73 (d, 2H), 8.50 (s, 1H), 8.23 (d, 1H),8.08 (s, 1H), 7.92 (d, 1H), 7.84 (s, 1H), 7.83 (d, 2H), 7.74 (t, 1H),7.59 (d, 1H), 6.88 (d, 1H).

Example 7 3-bromo-6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indole

The target compound was prepared as in Example 1 using6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indole (70 mg, 0.222 mmol) and4-bromopyridine hydrochloride (40 mg, 0.222 mmol).

¹H NMR (400 MHz, DMSO-d₆) δ 8.75 (d, 2H), 8.52 (s, 1H), 8.26-8.21 (m,3H), 8.10 (s, 1H), 7.85 (d, 2H), 7.75 (t, 1H), 7.72-7.70 (m, 2H).

Example 83-bromo-1-(2-(methylthio)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole

Sodium hydride (60% in mineral oil, 38 mg, 0.946 mmol) was added to amixture solution of 3-bromo-6-(3-nitrophenyl)-1H-indole (100 mg, 0.315mmol) in anhydrous DMF (2 mL) at room temperature. 10 minutes later,4-chloro-2-(methylthio)pyrimidine (44 μL, 0.378 mmol) was added. Afterstirring at room temperature for 2 hours, water was added. Thus producedsolid was filtered and dried. The target compound (140 mg) was obtainedas white solid.

MS m/z [M+1] 441.11, 443.13.

Example 9 3-bromo-1-(6-chloropyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole

Sodium hydride (60% in mineral oil, 114 mg, 2.84 mmol) was added to amixture solution of 3-bromo-6-(3-nitrophenyl)-1H-indole (450 mg, 1.42mmol) and 4,6-dichloropyrimidine (212 mg, 1.42 mmol) in anhydrous DMF(10 mL) at room temperature. After stirring at room temperature for 5hours, followed by addition of ice, the mixture was added to icy water.After stirring at room temperature for 12 hours, the produced solid wasfiltered, washed with water, and then dried. The target compound (600mg) was obtained as yellow solid.

¹H NMR (400 MHz, CDCl₃) δ8.96 (s, 1H), 8.93 (s, 1H), 8.54 (s, 1H), 8.25(dd, 1H), 8.01 (d, 1H), 7.79 (s, 1H), 7.72 (d, 1H), 7.68 (t, 1H), 7.63(d, 1H), 7.41 (s, 1H); MS m/z [M+1] 429.05, 431.03, 433.01.

Example 106-(3-bromo-6-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine

DMF (10 mL) was added to a mixture of3-bromo-1-(6-chloropyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole (500 mg,1.16 mmol), methylamine hydrochloride (393 mg, 5.82 mmol) and potassiumcarbonate (1.60 g, 11.6 mmol). After stirring at 80° C. for 3 hours andthen cooling to room temperature, the reaction solution was added to icywater. After stirring at room temperature for 15 hours, thus producedsolid was filtered, washed with water and then dried. The targetcompound (500 mg) was obtained as yellow solid.

¹H NMR (400 MHz, CDCl₃) δ 8.74 (s, 1H), 8.57 (s, 1H), 8.54 (m, 1H), 8.22(d, 1H), 8.01 (d, 1H), 7.81 (s, 1H), 7.70 (d, 1H), 7.65 (t, 1H), 7.57(d, 1H) 6.33 (s, 1H), 3.07 (d, 3H); MS m/z [M+1] 424.16, 426.16.

Example 113-bromo-1-(6-chloropyrimidin-4-yl)-6-(4-methoxyphenyl)-1H-indole

The target compound was prepared as in Example 9 using3-bromo-6-(4-methoxyphenyl)-1H-indole (500 mg, 1.65 mmol) and4,6-dichloropyrimidine (247 mg, 1.65 mmol).

¹H NMR (400 MHz, CDCl₃) δ8.91 (s, 1H), 8.74 (s, 1H), 7.76 (s, 1H), 7.64(d, 1H), 7.62 (d, 2H), 7.57 (d, 1H), 7.40 (s, 1H), 7.04 (d, 2H), 3.89(s, 3H); MS m/z [M+1] 413.89, 415.88.

Example 126-(3-bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine

The target compound was prepared as in Example 10 using3-bromo-1-(6-chloropyrimidin-4-yl)-6-(4-methoxyphenyl)-1H-indole (400mg, 0.96 mmol) and methylamine hydrochloride (326 mg, 4.8 mmol).

¹H NMR (400 MHz, CDCl₃) δ8.59 (s, 1H), 8.55 (s, 1H), 7.79 (s, 1H), 7.62(d, 1H), 7.60 (d, 2H), 7.51 (d, 1H), 7.02 (d, 2H), 6.35 (s, 1H), 5.13(br, 1H), 3.86 (s, 3H), 3.04 (d, 3H); MS m/z [M+1] 408.96, 410.98.

Example 13 tert-butyl4-(3-(4-methoxyphenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate

DMF/water (4:1, 2 mL) was added to a mixture of tert-butyl4-(3-bromo-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate (29mg, 0.0636 mmol), potassium carbonate (18 mg, 0.13 mmol) and4-methoxyphenylboronic acid (11 mg, 0.070 mmol) and the dissolved gaswas removed. After adding Pd(dppf) Cl₂ (10.4 mg, 0.013 mmol), themixture was stirred at room temperature for 14 hours. After adding ethylacetate and water, the mixture was filtered using a diatomite pad. Afterseparation of the organic layer, the aqueous layer was extracted withethyl acetate. The collected organic layer was washed with brine andconcentrated under reduced pressure by drying with anhydrous magnesiumsulfate. The residue was purified by chromatography (silica gel,EA:Hx=1:4 1:1). The target compound (31 mg) was obtained as white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.65 (d, J=6 Hz, 2 H), 7.51 (d, J=8.4 Hz, 1H), 7.28 (d, 6 Hz, 2 H), 7.13 (d, J=8.8 Hz, 2 H), 6.96 (dd, J=1.6, 10.4Hz, 1 H), 6.88 (d, J=8.8 Hz, 2 H), 6.82 (s, 1 H), 6.71 (s, 1 H), 3.74(s, 3 H), 3.46 (br s, 4 H), 3.02 (br s, 4 H), 1.40 (s, 9 H).

Example 143-(4-methoxyphenyl)-6-(piperazin-1-yl)-1-(pyridin-4-yl)-1H-indole

Trifluoroacetic acid (46 μL, 0.059 mmol) was added to a mixture solutionof tert-butyl4-(3-(4-methoxyphenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate(29 mg, 0.059 mmol) in methylene chloride (1 mL) at room temperature.After stirring for 3 hours, the reaction solution was concentrated underreduced pressure. After adding ethyl acetate and saturated sodiumbicarbonate aqueous solution, the mixture was extracted with ethylacetate. The collected organic layer was washed with brine andconcentrated under reduced pressure by drying with anhydrous magnesiumsulfate. The target compound (14 mg, 64%) was obtained as yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.65 (br d, J=6 Hz, 2 H), 7.48 (d, J=8.8 Hz,1 H), 7.28 (br d, J=6 Hz, 2 H), 7.13 (d, =8.8 Hz, 2 H), 6.92 (dd, J=2,8.8 Hz, 1 H), 6.88 (d, J=8.8 Hz, 2 H), 6.77 (s, 1 H), 6.69 (s, 1 H),3.73 (s, 3 H), 2.97 (br s, 4 H), 2.81 (br s, 4 H).

Example 15 4-(6-(piperazin-1-yl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenol

Boron tribromide (BBr₃, 17 μL, 0.182 mmol) was added to a mixturesolution of3-(4-methoxyphenyl)-6-(piperazin-1-yl)-1-(pyridin-4-yl)-1H-indole (14mg, 0.036 mmol) in methylene chloride (0.5 mL) at −78° C. After stirringat room temperature for 15 hours, the reaction solution was added to amixture solution of saturated sodium bicarbonate aqueous solution andethyl acetate and then extracted with ethyl acetate. The collectedorganic layer was washed with brine and concentrated under reducedpressure by drying with anhydrous magnesium sulfate. The target compound(12 mg) was obtained as yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 9.60 (br s, 1 H), 8.64 (d, J=6.4 Hz, 2 H),7.46 (d, J=11.2 Hz, 1 H), 7.26 (d, J=6.4 Hz, 2 H), 7.01 (d, J=11.6 Hz, 2H), 6.91 (d, J=11.2 Hz, 1 H), 6.77 (s, 1 H), 6.68 (d, J=11.2 Hz, 2 H),6.63 (s, 1 H), 2.97 (br s, 4 H), 2.80 (br s, 4 H).

Example 16 tert-butyl4-(3-(4-(tert-butoxycarbonyloxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate

4-(6-(piperazin-1-yl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenol (13 mg,0.035 mmol) and methylene chloride (2 mL) were added to a reactor and acatalytic amount of N,N-dimethylaminopyridine, triethylamine (6 μL,0.039 mmol) and (Boc)₂O were sequentially added at 0° C. After stirringat 0° C. for 1 hour and then at room temperature for 3 hours, water andethyl acetate were added. After extraction with ethyl acetate, thecollected organic layer was washed with brine and concentrated underreduced pressure by drying with anhydrous magnesium sulfate. The residuewas purified by chromatography (silica gel, EA only). The targetcompound (12 mg, 60%) was obtained as yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.66 (br d, J=6.4 Hz, 2 H), 7.54 (d, J=8.8Hz, 1 H), 7.31 (br d, J=6.4 Hz, 2 H), 7.24 (d, J=8.8 Hz, 2 H), 7.15 (d,J=8.8 Hz, 2 H), 6.98 (br d, J=10.4 Hz, 1 H), 6.83 (br s, 2 H), 3.45 (brs, 4 H), 3.04 (br s, 4 H), 1.48 (s, 9 H), 1.41 (s, 9 H).

Example 17 tert-butyl4-(3-(4-hydroxyphenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate

2 N sodium hydroxide aqueous solution (18 μL, 0.035 mmol) was added to amixture solution of tert-butyl4-(3-(4-(tert-butoxycarbonyloxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate(10 mg, 0.018 mmol) in methanol (0.5 mL) at room temperature. Afterstirring at room temperature for 3.5 hours, followed by addition ofwater, the mixture was extracted with ethyl acetate. The collectedorganic layer was washed with brine and concentrated under reducedpressure by drying with anhydrous magnesium sulfate. The target compoundwas obtained as white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.64 (br d, J=6 Hz, 2 H), 7.49 (d, J=8.8 Hz,1 H), 7.26 (br d, J=6 Hz, 2 H), 7.01 (d, J=8.8 Hz, 2 H), 6.93 (d, J=8.4Hz, 1 H), 6.82 (s, 1 H), 6.69 (d, J=8.8 Hz, 2 H), 6.65 (s, 1 H), 3.43(br s, 4 H), 3.01 (br s, 4 H), 1.40 (s, 9 H).

Example 18 tert-butyl4-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate

2-Chloro-N,N-dimethylethylamine hydrochloride (7.3 mg, 0.051 mmol) andcesium carbonate (33 mg, 0.101 mmol) were added to a mixture solution oftert-butyl4-(3-(4-hydroxyphenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate(12 mg, 0.025 mmol) in DMF (1 mL). After room temperature stirring atroom temperature for 16 hours, followed by addition of water, themixture was extracted with ethyl acetate. The collected organic layerwas washed with brine and concentrated under reduced pressure by dryingwith anhydrous magnesium sulfate. The target compound was obtained aswhite solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.65 (d, J=6.4 Hz, 2 H), 7.51 (d, J=11.2 Hz,1 H), 7.28 (d, J=8 Hz, 2 H), 6.96 (br d, J=13.2 Hz, 1 H), 6.88 (d,J=11.2 Hz, 2 H), 6.83 (br s, 1 H), 6.71 (s, 1 H), 4.02 (t, J=7.2 Hz, 2H), 3.45 (br s, 4 H), 3.02 (br s, 4 H), 2.59 (t, J=7.2 Hz, 2 H), 2.19(s, 6 H), 1.41 (s, 9 H).

Example 19N,N-dimethyl-2-(4-(6-(piperazin-1-yl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenoxy)ethanamine

Trifluoroacetic acid (0.2 mL) was added to a mixture solution oftert-butyl4-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)piperazine-1-carboxylate(4.1 mg, 7.6 μmol) in methylene chloride (0.2 mL) at room temperature.After stirring for 15 hours, the reaction solution was concentratedunder reduced pressure. After adding ethyl acetate and saturated sodiumbicarbonate aqueous solution, the mixture was extracted with ethylacetate. The collected organic layer was washed with brine andconcentrated under reduced pressure by drying with anhydrous magnesiumsulfate. The target compound was obtained as white solid.

¹H NMR (400 MHz, DMSO-d₆) δ 8.65 (br d, J=6 Hz, 2 H), 7.54 (d, J=8.8 Hz,1 H), 7.30 (br d, J=6 Hz, 2 H), 7.13 (d, J=8.8 Hz, 2 H), 6.97 (dd, J=3,8.4 Hz, 1 H), 6.89 (d, J=8.8 Hz, 2 H), 6.83 (s, 1 H), 6.73 (s, 1 H),4.05 (t, J=6.8 Hz, 2 H), 3.22 (br s, 4 H), 3.19 (br s, 4 H), 2.51 (t,J=6.8 Hz, 2 H), 2.27 (s, 6 H).

Example 203-(4-methoxyphenyl)-6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indole

The target compound was prepared as in Example 13 using3-bromo-6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indole (97 mg, 0.222 mmol)and 4-methoxyphenylboronic acid (37 mg, 0.244 mmol).

¹H NMR (400 MHz, DMSO-d₆) δ 8.76 (d, 2H), 8.49 (s, 1H), 8.26 (d, 1H),8.21 (d, 1H), 8.16 (s, 1H), 8.05 (d, 1H), 7.9) (d, 2H), 7.78*t, 1H),7.73 (d, 2H), 7.67 (d, 1H), 7.10 (d, 1H), 3.78 (s, 3H).

Example 21 4-(6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenol

The target compound was prepared as in Example 15 using3-(4-methoxyphenyl)-6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indole (58 mg,0.138 mmol) and boron tribromide (BBr₃, 65 μL, 0.691 mmol).

¹H NMR (400 MHz, DMSO-d₆) δ 9.53 (s, 1H), 8.75 (d, 2H), 8.52 (m, 1H),8.26 (d, 1H), 8.21 (d, 1H), 8.15 (s, 1H), 8.09 (s, 1H), 8.03 (d, 1H),7.89 (d, 2H), 7.78 (t, 1H), 7.66 (d, 1H), 7.61 (d, 2H), 6.92 (d, 2H).

Example 22 4-(6-(3-aminophenyl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenol

Methanol (2 mL) was added to4-(6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenol (4.6 mg,0.0113 mmol) and 10% (w/w) palladium-carbon (Pd—C, 5.0 mg). The mixturewas stirred at room temperature for 12 hours under hydrogen gas (1 atm).The reaction solution was filtered using a diatomite pad andconcentrated under reduced pressure. The target compound was obtained asbrown solid.

¹H NMR (400 MHz, DMSO-d₆) δ9.50 (s, 1H), 8.74 (d, 2H), 8.01 (s, 1H),7.94 (d, 1H), 7.91 (s, 1H), 7.83 (d, 2H), 7.60 (d, 2H), 7.47 (d, 1H),7.11 (t, 1H), 6.90 (d, 2H), 6.89 (s, 1H), 6.82 (d, 1H), 6.55 (d, 1H),5.15 (s, 2H).

Example 23N,N-dimethyl-2-(4-(6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenoxy)ethanamine

The target compound was prepared as in Example 18 using4-(6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenol (32 mg, 0.079mmol), 2-chloro-N,N-dimethylethylamine hydrochloride (34 mg, 0.237 mmol)and cesium carbonate (154 mg, 0.237 mmol).

¹H NMR (400 MHz, DMSO-d₆) δ8.76 (d, 2H), 8.53 (t, 1H), 8.26 (d, 1H),8.21 (dd, 1H), 8.17 (s, 1H), 8.14 (s, 1H), 8.05 (d, 1H), 7.91 (d, 2H),7.78 (t, 1H), 7.72 (d, 2H), 7.68 (dd, 1H), 7.10 (d, 2H), 4.13 (t, 2H),2.67 (t, 2H), 2.26 (s, 6H).

Example 243-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)benzenamine

The target compound was prepared as in Example 22 usingN,N-dimethyl-2-(4-(6-(3-nitrophenyl)-1-(pyridin-4-yl)-1H-indol-3-yl)phenoxy)ethanamine(7.5 mg, 0.016 mmol).

¹H NMR (400 MHz, DMSO-d₆) δ8.75 (d, 2H), 8.08 (s, 1H), 7.96 (d, 1H),7.92 (s, 1H), 7.84 (d, 2H), 7.71 (d, 2H), 7.48 (d, 1H), 7.10 (t, 1H),7.08 (d, 2H), 6.90 (s, 1H), 6.88 (d, 1H), 6.55 (d, 1H), 5.15 (s, 2H),4.13 (t, 2H), 2.67 (t, 2H), 2.26 (s, 6H).

Example 25N-(3-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)phenyl)acetamide

Acetic anhydride (4.8 μL, 0.5.1 μmol) was added to a mixture solution of3-(3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(pyridin-4-yl)-1H-indol-6-yl)benzenamine(2.2 mg, 4.9 μmol) in pyridine (0.4 mL) at room temperature. Afterstirring for 15 hours at room temperature, the reaction solution wasadded to saturated sodium bicarbonate aqueous solution and thenextracted with ethyl acetate. The collected organic layer was washedwith brine and concentrated under reduced pressure by drying withanhydrous magnesium sulfate. The residue was purified by chromatography(preparative TLC, DCM:MeOH=10:1). The target compound (1.5 mg) wasobtained as white solid.

¹H NMR (400 MHz, DMSO-d₆) δ10.03 (s, 1H), 8.75 (d, 2H), 8.11 (s, 1H),8.01 (d, 1H), 7.97 (s, 1H), 8.85 (d, 2H), 7.72 (d, 2H), 7.53 (d, 1H),7.50 (d, 1H), 7.40 (t, 1H), 7.39 (s, 1H), 7.09 (d, 2H), 6.55 (d, 1H),4.13 (t, 2H), 2.67 (t, 2H), 2.26 (s, 6H), 2.06 (s, 3H).

Example 266-(6-(4-methoxyphenyl)-3-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine

DMF (5 mL) was added to a mixture of6-(3-bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(200 mg, 0.49 mmol), K₃PO₄ (312 mg, 0.885 mmol) and 3-nitrophenylboronicacid (123 mg, 0.74 mmol) and then the dissolved gas was removed. Afteradding Pd(PPh₃)₄ (85 mg, 0.075 mmol), the mixture was stirred at 100° C.for 4 hours. After adding ethyl acetate and water and filtering using adiatomite pad, the organic layer was separated and the aqueous layer wasextracted with ethyl acetate. The collected organic layer was washedwith brine and concentrated under reduced pressure by drying withanhydrous magnesium sulfate. The residue was purified by chromatography(silica gel, EA:Hx=1:4-1:1). The target compound (70 mg) was obtained aswhite solid.

¹H NMR (400 MHz, CDCl₃) δ 8.60 (s, 1H), 8.59 (s, 1H), 8.58 (s, 1H), 8.20(d, 1H), 8.06 (d, 1H), 8.01 (s, 1H), 7.93 (d, 1H), 7.65 (t, 1H), 7.64(d, 2H), 7.55 (d, 1H), 7.03 (d, 2H), 6.50 (s, 1H), 5.20 (br, 1H), 3.89(s, 3H), 3.07 (d, 3H); MS m/z [M+1] 452.06, 453.06, 454.07.

Example 276-(3-(3-aminophenyl)-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine

Methanol/DMF (2:1, 20 mL) was added to6-(6-(4-methoxyphenyl)-3-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(70 mg, 0.16 mmol) and Raney nickel (Raney Ni; about 50 mg). The mixturewas stirred at room temperature for 12 hours under hydrogen gas (1 atm).The reaction solution was filtered using a diatomite pad andconcentrated under reduced pressure. The target compound (60 mg) wasobtained as brown solid.

MS m/z [M+1] 422.08, 423.09, 424.12.

Example 28N-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)acetamide

Acetic anhydride (20.3 μL, 0.214 mmol) was added to a mixture solutionof6-(3-(3-aminophenyl)-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(30 mg, 0.071 mmol) and pyridine (28.7 μL, 0.355 mmol) in methylenechloride (2 mL) at room temperature. After stirring for 1 hour at roomtemperature, the reaction solution was added to saturated sodiumbicarbonate aqueous solution and then extracted with ethyl acetate. Thecollected organic layer was washed with brine and concentrated underreduced pressure by drying with anhydrous magnesium sulfate. The residuewas purified by chromatography (preparative HPLC). The target compound(15 mg) was obtained as white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 1H0, 8.57 (s, 1H), 7.95 (d, 1H), 7.93(d, 1H), 7.87 (s, 1H), 7.62 (d, 2H), 7.49 (d, 1H), 7.45 (m, 3H), 7.03(d, 2H), 6.44 (s, 1H), 5.20 (br, 1H), 3.88 (s, 3H), 3.05 (d, 3H), 2.24(s, 3H); MS m/z [M+1] 464.10, 465.10, 466.08.

Example 29 ethyl4-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzoate

DMF (5 mL) was added to a mixture of6-(3-bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(200 mg, 0.49 mmol), K₃PO₄ (312 mg, 0.885 mmol) and4-(ethoxycarbonyl)phenylboronic acid (143 mg, 0.74 mmol) and then thedissolved gas was removed. After adding Pd(PPh₃)₄ (85 mg, 0.075 mmol),the mixture was stirred at 100° C. for 4 hours. After adding ethylacetate and water and filtering using a diatomite pad, the organic layerwas separated and the aqueous layer was extracted with ethyl acetate.The collected organic layer was washed with brine and concentrated underreduced pressure by drying with anhydrous magnesium sulfate. The residuewas purified by chromatography (silica gel, EA:Hx=1:4-1:1). The targetcompound (70 mg) was obtained as white solid.

¹H NMR (400 MHz, CDCl₃) δ8.59 (s, 1H), 8.56 (s, 1H), 8.16 (d, 2H), 7.97(s, 1H), 7.95 (d, 1H), 7.80 (d, 2H), 7.63 (d, 2H), 7.53 (d, 1H), 7.03(d, 2H), 6.49 (s, 1H), 5.16 (br, 1H), 4.43 (q, 2H), 3.88 (s, 3H), 3.06(d, 3H), 1.44 (t, 3H); MS m/z [M+1] 479.12, 480.07, 481.08.

Example 304-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzoate

1 M sodium hydroxide aqueous solution (5 mL) was added to a mixturesolution of ethyl4-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzoate(70 mg, 0.146 mmol) in THF/methanol (1:1, 10 mL) at room temperature.After stirring for 12 hours at room temperature, the reaction solutionwas adjusted to pH 4 using 1 N hydrochloric acid aqueous solution. Afteradding water, the mixture was extracted with methylene chlorideincluding a small amount of methanol. The collected organic layer wasconcentrated under reduced pressure by drying with anhydrous magnesiumsulfate. The target compound was obtained as white solid.

¹H NMR (400 MHz, CDCl₃+MeOD) δ8.37 (s, 1H), 8.35 (s, 1H), 8.01 (d, 2H),7.87 (s, 1H), 7.78 (d, 1H), 7.66 (d, 2H), 7.48 (d, 2H), 7.42 (d, 1H),6.87 (d, 2H), 6.53 (br, 1H), 3.73 (s, 3H), 2.92 (s, 3H); MS m/z [M+1]451.05, 452.06, 453.03.

Example 314-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)-N-(2-morpholinoethyl)benzamide

O-(7-Azabenzotriazol-1-yl)-N,N,N,N-tetramethyluroniumhexafluorophosphate (HATU; 63 mg, 0.167 mmol) was added to a mixturesolution of4-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzoate(50 mg, 0.111 mmol), 2-morpholinoethanamine (14.6 μL, 0.111 mmol) anddiisopropylethylamine (DIPEA; 29 μL, 0.167 mmol) in THF (2 mL) at roomtemperature. 2 hours later, the mixture was added to saturated sodiumbicarbonate aqueous solution and then extracted with methylene chloride.The collected organic layer was washed with brine and concentrated underreduced pressure by drying with anhydrous magnesium sulfate. The residuewas purified by chromatography (preparative HPLC). The target compound(15 mg) was obtained as white solid.

¹H NMR (400 MHz, CDCl₃+MeOD) δ 8.28 (br, 2H), 7.78 (s, 1H), 7.74 (d,1H), 7.73 (d, 2H), 7.62 (d, 2H), 7.43 (d, 2H), 7.31 (d, 2H), 6.81 (d,2H), 6.41 (br, 1H), 3.67 (s, 3H), 3.57 (m, 4H), 3.39 (t, 2H), 2.80 (s,3H), 2.46 (t, 2H), 2.38 (m, 4H); MS m/z [M+1] 563.16, 564.13, 565.16.

Example 323-(4-methoxyphenyl)-1-(2-(methylthio)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole

DMF (2 mL) was added to a mixture of3-bromo-1-(2-(methylthio)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole(130 mg, 0.295 mmol), K₃PO₄ (188 mg, 0.885 mmol) and4-methoxyphenylboronic acid (90 mg, 0.59 mmol) and then the dissolvedgas was removed. After adding Pd(PPh₃)₄ (68 mg, 0.055 mmol), the mixturewas stirred at 100° C. for 4 hours. After adding ethyl acetate and waterand then filtering using a diatomite pad, the organic layer wasseparated and the aqueous layer was extracted with ethyl acetate. Thecollected organic layer was washed with brine and concentrated underreduced pressure by drying with anhydrous magnesium sulfate. The residuewas purified by chromatography (silica gel, EA:Hx=1:4-1:1). The targetcompound (96 mg) was obtained as white solid.

MS m/z [M+1] 469.18.

Example 333-(4-methoxyphenyl)-1-(2-(methylsulfinyl)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole

m-Chloroperoxybenzoic acid (m-CPBA; 70%, 95 mg, 0.384 mmol) was added toa mixture solution of3-(4-methoxyphenyl)-1-(2-(methylthio)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole(90 mg, 0.192 mmol) in methylene chloride (10 mL) at 0° C. 2 hourslater, after adding saturated sodium bicarbonate aqueous solution at 0°C., the mixture was extracted with ethyl acetate. The collected organiclayer was washed with brine and concentrated under reduced pressure bydrying with anhydrous magnesium sulfate. The target compound (90 mg) wasobtained as white solid.

¹H NMR (400 MHz, CDCl₃) δ 9.37 (s, 1H), 8.82 (d, 1H), 8.61 (s, 1H), 8.21(d, 1H), 7.95 (d, 1H), 7.79 (s, 1H), 7.68 (d, 1H), 7.67 (t, 1H), 7.64(d, 2H), 7.45 (d, 1H), 7.08 (d, 2H), 6.79 (d, 1H), 3.91 (s, 3H), 3.08(s, 3H); MS m/z [M+1] 485.25.

Example 344-(3-(4-methoxyphenyl)-6-(3-nitrophenyl)-1H-indol-1-yl)pyrimidin-2-amine

2.0 M ammonia isopropanol solution (2 mL) was added to3-(4-methoxyphenyl)-1-(2-(methylsulfinyl)pyrimidin-4-yl)-6-(3-nitrophenyl)-1H-indole(90 mg) and then stirred at 100° C. for 3 hours in a sealed state. Aftercooling to room temperature, thus produced solid was filtered. Afterwashing with isopropanol and then drying, the target compound (50 mg)was obtained as white solid.

¹H NMR (400 MHz, CDCl₃) δ8.82 (s, 1H), 8.57 (s, 1H), 8.37 (d, 1H0, 8.22(d, 1H), 8.02 (d, 1H), 7.95 (d, 1H), 7.81 (s, 1H), 7.65 (t, 1H), 7.63(d, 2H), 7.56 (d, 1H), 7.06 (d, 2H), 6.84 (d, 1H), 5.16 (s, 2H), 3.90(s, 3H); MS m/z [M+1] 438.23.

Example 356-(3-(4-methoxyphenyl)-6-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine

DMF (5 mL) was added to a mixture of6-(3-bromo-6-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(300 mg, 0.710 mmol), K₃PO₄ (452 mg, 2.13 mmol) and4-methoxyphenylboronic acid (215 mg, 1.41 mmol) and then the dissolvedgas was removed. After adding Pd(PPh₃)₄ (123 mg, 0.11 mmol), the mixturewas stirred at 120° C. for 2 hours. After adding ethyl acetate and waterand then filtering using a diatomite pad, the organic layer wasseparated and the aqueous layer was extracted with ethyl acetate. Thecollected organic layer was washed with brine and concentrated underreduced pressure by drying with anhydrous magnesium sulfate. The residuewas purified by chromatography (silica gel, EA:Hx=1:4→1:1). The targetcompound was obtained as white solid.

¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 8.59 (s, 1H), 8.56 (m, 1H), 8.21(d, 1H), 8.53 (d, 1H), 7.95 (d, 1H), 7.82 (s, 1H), 7.66 (d, 2H), 7.65(t, 1H), 7.56 (d, 1H), 7.06 (d, 2H), 6.42 (s, 1H), 5.16 (br, 1H), 3.90(s, 3H), 3.07 (d, 3H); MS m/z [M+1] 452.04, 453.04.

Example 366-(6-(3-aminophenyl)-3-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine

Methanol/DMF (1:1, 20 mL) was added to6-(3-(4-methoxyphenyl)-6-(3-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(100 mg, 0.22 mmol) and Raney nickel (about 50 mg). The mixture wasstirred at room temperature for 24 hours under hydrogen gas (1 atm). Thereaction solution was filtered using a diatomite pad and thenconcentrated under reduced pressure. The target compound was obtained asbrown solid.

¹H NMR (400 MHz, CDCl₃) δ8.60 (s, 1H), 7.91 (d, 1H), 7.82 (s, 1H), 7.69(t, 1H), 7.66 (d, 2H), 7.49 (m, 3H), 7.09 (d, 1H), 7.04 (d, 2H), 6.45(s, 1H), 5.10 (br, 1H), 3.88 (s, 3H), 3.05 (d, 3H); MS m/z [M+1] 422.11,423.11.

Example 371-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea

1-Chloro-4-isocyanato-2-(trifluoromethyl)benzene (15.8 mg, 0.071 mmol)was added to a mixture solution of6-(6-(3-aminophenyl)-3-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(20 mg, 0.047 mmol) in THF (1 mL) at room temperature. After stirring atroom temperature for 12 hours, the reaction solution was concentratedunder reduced pressure. The residue was purified by chromatography(silica gel, EA:Hx=1:1; DCM:MeOH=100:1; 20:1). The target compound wasobtained as yellow solid.

MS m/z [M+1] 643.08, 645.01.

Example 381-(3,4-dichlorophenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea

MS m/z [M+1] 608.91, 610.91.

Example 391-(2-methoxyphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea

MS m/z [M+1] 571.13, 572.09.

Example 401-(2-fluorophenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea

MS m/z [M+1] 559.09, 560.06.

Example 411-cyclohexyl-3-(3-(3-(4-methoxyphenyl)-1-(6-methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea

MS m/z [M+1] 547.15, 548.13.

Example 42N-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)-3-morpholino-5-(trifluoromethyl)benzamide

HATU (100 mg, 0.260 mmol) was added to a mixture solution of3-morpholino-5-(trifluoromethyl)benzoate (54 mg, 0.195 mmol),6-(6-(3-aminophenyl)-3-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(55 mg, 0.130 mmol) and DIPEA (45 μL, 0.26 mmol) in THF (2 mL) at roomtemperature. 12 hours later, the mixture was added to saturated sodiumbicarbonate aqueous solution and then extracted with methylene chloride.The collected organic layer was washed with brine and then concentratedunder reduced pressure by drying with anhydrous magnesium sulfate. Theresidue was purified by chromatography (preparative HPLC). The targetcompound was obtained as yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 10.47 (s, 1H), 8.50 (br, 1H), 8.08 (s, 1H),7.95 (d, 1H), 7.83 (m, 1H), 7.75-7.69 (m, 5H), 7.55 (d, 2H), 7.52-7.48(m, 2H), 7.40 (s, 1H), 7.09 (d, 2H), 6.80 (s, 1H), 3.82 (s, 3H), 3.77(m, 4H), 3.30 (m, 4H), 2.90 (s, 3H); MS m/z [M+1] 679.08, 680.03,681.10.

Example 43N-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)-4-methyl-3-nitrobenzamide

¹H NMR (400 MHz, DMSO-d₆) δ 10.58 (s, 1H), 8.61 (d, 1H), 8.48 (br, 1H),8.24 (d, 1H), 8.09 (m, 1H), 7.95 (d, 1H), 7.88 (m, 1H), 7.76-7.73 (m,3H), 7.55 (d, 1H), 7.52-7.44 (m, 4H), 7.09 (d, 2H), 6.78 (br, 1H), 3.96(s, 3H), 2.90 (d, 3H), 2.66 (s, 3H); MS m/z [M+1] 585.05, 586.06,587.06.

Example 44N-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, DMSO-d₆) δ10.73 (s, 1H), 9.62 (br, 1H), 8.63 (s, 1H),8.49-8.44 (m, 3H), 8.15 (s, 1H), 8.10 (m, 1H), 7.98 (d, 1H), 7.87 (m,3H), 7.72 (d, 2H), 7.65-7.51 (m, 5H), 7.09 (d, 2H), 6.97 (d, 1H), 6.78(br, 1H), 3.82 (s, 3H), 2.90 (d, 3H), 2.35 (s, 3H); MS m/z [M+1] 674.04,675.05, 676.02.

Example 451-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)urea

MS m/z [M+1] 643.12, 645.06.

Example 464-chloro-N-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)-3-(trifluoromethyl)benzamide

MS m/z [M+1] 628.07, 630.09.

Example 47N-cyclopropyl-4-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzamide

MS m/z [M+1] 490.01.

Example 481-(2,6-dimethylphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea

MS m/z [M+1] 569.34.

Example 491-(4-(4-ethylpiperazin-1-yl)-2-methoxyphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea

MS m/z [M+1] 683.48.

Example 501-(5-chloro-2,4-dimethoxyphenyl)-3-(3-(3-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-6-yl)phenyl)urea

MS m/z [M+1] 635.36.

Example 51N-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)cyclopropanecarboxamide

MS m/z [M+1] 490.20.

Example 52N-(3-(6-(4-methoxyphenyl)-1-(6-(methylamino)pyrimidin-4-yl)-1H-indol-3-yl)phenyl)cyclopropanesulfonamide

6-(3-(3-Aminophenyl-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(15 mg, 0.036 mmol) and triethylamine (99 μL, 0.712 mmol) were dissolvedin tetrahydrofuran (1 mL). After adding cyclopropanesulfonyl chloride(54 μL, 0.534 mmol) at room temperature, the mixture was stirred at roomtemperature for 2 hours. The reaction solution was added to saturatedsodium bicarbonate solution and then extracted with ethyl acetate. Theorganic layer was washed with brine and then concentrated under reducedpressure by drying with magnesium sulfate. The residue was purified bychromatography (silica gel, EtOAc:hexane=2:1→1:1). The target compoundwas obtained.

MS m/z [M+1] 526.13.

Example 536-(6-(4-methoxyphenyl)-1H,1′H-3,6′-biindol-1-yl)-N-methylpyrimidin-4-amine

6-(3-Bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine(50 mg, 0.074 mmol), K₃PO₄ (47.1 mg, 0.222 mmol) and6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (27 mg, 0.111mmol) were dissolved in dimethylformamide (2 mL) and then Pd(PPh₃)₄(12.83 mg, 0.011 mmol) was added. After stirring at 120° C. for 3 hours,followed by addition of ethyl acetate and water, the reaction solutionwas filtered using a diatomite pad. The aqueous layer was extracted withethyl acetate and the collected organic layer was washed with brine andthen concentrated under reduced pressure by drying with magnesiumsulfate. The residue was purified by chromatography (silica gel,EtOAc:hexane=1:10→1:4→1:2). The target compound was obtained as brownsolid.

MS m/z [M+1] 446.13.

Example 546-(6-(4-methoxyphenyl)-3-(4-nitrophenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine

MS m/z [M+1] 452.06.

Example 556-(3-(4-aminophenyl)-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-methylpyrimidin-4-amine

MS m/z [M+1] 422.13.

Example 566-(3-bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-(2-morpholinoethyl)pyrimidin-4-amine

MS m/z [M+1] 507.90.

Example 576-(3-bromo-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-cyclopropylpyrimidin-4-amine

MS m/z [M+1] 434.82.

Example 586-(6-(4-methoxyphenyl)-3-(3-nitrophenyl)-1H-indol-1-yl)-N-(2-morpholinoethyl)pyrimidin-4-amine

MS m/z [M+1] 550.96.

Example 59N-cyclopropyl-6-(6-(4-methoxyphenyl)-3-(3-(nitrophenyl)-1H-indol-1-yl)pyrimidin-4-amine

MS m/z [M+1] 477.92.

Example 606-(3-(3-aminophenyl)-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-(2-morpholinoethyl)pyrimidin-4-amine

MS m/z [M+1] 521.01.

Example 616-(3-(3-aminophenyl)-6-(4-methoxyphenyl)-1H-indol-1-yl)-N-cyclopropylpyrimidin-4-amine

MS m/z [M+1] 448.00.

Example 62 ethyl4-(6-(4-methoxyphenyl)-1-(6-(2-morpholinoethylamino)pyrimidin-4-yl)-1H-indol-3-yl)benzoate

MS m/z [M+1] 578.00.

FORMULATION EXAMPLES

The novel compound represented by Chemical Formula 1 may be preparedinto various formulations depending on purposes. The following examplesillustrate some formulations comprising the compound represented byChemical Formula 1 as an active ingredient, but they do not limit thepresent invention.

Formulation Example 1 Tablet (Direct Compression)

The active ingredient (5.0 mg) was sieved, mixed with lactose (14.1 mg),crospovidone USNF (0.8 mg) and magnesium stearate (0.1 mg), and thencompressed into a tablet.

Formulation Example 2 Tablet (Wet Granulation)

The active ingredient (5.0 mg) was sieved and mixed with lactose (16.0mg) and starch (4.0 mg). An adequate amount of the resulting solutionwas added to Polysorbate 80 (0.3 mg) dissolved in pure water, and thenformed into granules. After drying, the granules were sieved and mixedwith colloidal silicon dioxide (2.7 mg) and magnesium stearate (2.0 mg).The granules were compressed into a tablet.

Formulation Example 3 Powder and Capsule

The active ingredient (5.0 mg) was sieved and mixed with lactose (14.8mg), polyvinylpyrrolidone (10.0 mg) and magnesium stearate (0.2 mg). Themixture was filled in a hard No. 5 gelatin capsule using an adequateapparatus.

Formulation Example 4 Injection

The active ingredient (100 mg) was mixed with mannitol (180 mg),Na₂HPO₄.12H₂O (26 mg) and distilled water (2974 mg) to prepare aninjection.

TEST EXAMPLES Test Example 1 Measurement of B-Raf Kinase Activity(Kinase Cascade Assay)

(1) Activation of MAP Kinase 2/Erk2 by B-Raf

Magnesium/ATP solution (500 μM ATP, 75 mM magnesium chloride) wasprepared (10 μL). Diluted B-Raf-V600E enzyme (2.5 μL) was added at afinal concentration of 1 ng/mL. and inactivated MEK1 (1.6 μL) was addedat a final concentration of 0.4 μg/mL. Then, inactivated MAP Kinase2/Erk2 (4 μL) was added at a final concentration of 1.0 μg/mL. The testcompound was prepared at a concentration of 10 mM in dimethylsulfoxide(DMSO) and diluted to various concentrations (DMSO 2.6%). The finalvolume was adjusted to 38 μL by adding Assay Dilution Butter I (ADBI)and the mixture was allowed to react at 30° C. for 30 minutes. 5 μL ofthe mixture solution was taken to perform the next process.

(2) Phosphorylation of Myelin Basic Protein (MBP)

The mixture solution (5 μL) was treated with assay dilution buffer (10μL) and then with myelin basic protein (MBP, 2 mg/mL, 10 μL). [γ-32P]ATP (100 μCi/container) diluted to 1/10 was added in 10 μL aliquots.After reaction at 30° C. for 2 10 minutes and then placing P81 paper ina scintillation vial, spotting was performed slowly using 25 μL of thereaction mixture. After washing 4 times with 0.75% phosphoric acid for10 minutes and washing once with acetone for 5 minutes, 5 mL ofscintillation cocktail was added to the scintillation vial. Signals wererecorded using a scintillation counter.

The B-Raf kinase inhibitory activity of some compounds represented byChemical Formula 1 is given in Table 1. IC₅₀ ranged from 0.12 to 20 μM.

TABLE 1 B-Raf-V600E kinase Test compounds inhibitory activity (IC₅₀, μM)Example 25 <10 Example 27 <10 Example 30 <10 Example 39 <10

Test Example 2 Measurement of Inhibitory Activity Against Proliferationof A375P Melanoma Cells

A375P cells purchased from ATCC were cultured in DMEM [10% FBS, 1%penicillin/streptomycin] at 37° C. in the presence of 5% CO₂. Thecultured A375P cells were harvested with 0.05% trypsin-0.02% EDTA andseeded in a 96-well plate at 5×10³ cells per well.

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay(CellTiter 96 Assay, Promega) was employed to measure cell viability.After adding 15 μL of a dye per well and culturing for 2 hours, thecells were treated with 100 μL of a stop solution and absorbance wasmeasured 24 hours later. The test compound was treated a day afterplating. The test compound had been sequentially diluted at 12concentrations from a 10 mM stock solution using sterilizeddimethylsulfoxide (DMSO) and treated with an amount of 0.5 μL.Absorbance at 590 nm was recorded using EnVision2103, and GI₅₀ value wascalculated using GraphPad Prism 4.0 software.

The compounds represented by Chemical Formula 1 exhibited inhibitoryactivity against proliferation of the A375P human melanoma cells withthe B-Raf-V600E mutants overexpressed. GI₅₀ ranged from 0.001 to 10 μM.The inhibitory activity against proliferation of the A375P cells of sometypical compounds according to the present invention is given in Table2.

TABLE 2 Inhibitory activity against proliferation Test compounds ofA375P cells (GI₅₀, μM) Example 9 <10 Example 13 <10 Example 14 <10Example 26 <10 Example 27 <10 Example 28 <10 Example 30 <10 Example 31<10 Example 33 <10 Example 37 <10 Example 39 <10 Example 45 <10

As described, since the 1,3,6-substituted indole compound represented byChemical Formula 1 or a pharmaceutically acceptable thereof exhibitsinhibitory activity for protein kinases, it is useful for preventing andtreating diseases caused by abnormal cell growth induced by proteinkinases, such as cancers selected from the group consisting of stomachcancer, lung cancer, liver cancer, colorectal cancer, small intestinecancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breastcancer, sclerosing adenoma, uterine cancer, cervical cancer, head andneck cancer, esophageal cancer, thyroid cancer, parathyroid cancer,renal cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer,leukemia, multiple myeloma, hematological malignancy such asmyelodysplastic syndrome, lymphoma such as Hodgkin's disease andnon-Hodgkin lymphoma and fibroadenoma.

While the present invention has been described with respect to thespecific embodiments, it will be apparent to those skilled in the artthat various changes and modifications may be made without departingfrom the spirit and scope of the invention as defined in the followingclaims.

What is claimed is:
 1. A method of inhibiting a Raf protein kinasecomprising contacting a cell with a pharmaceutical compositioncomprising an active ingredient that is a 1,3,6-substituted indolecompound represented by chemical formula 1, or a pharmaceuticallyacceptable salt thereof:

wherein X and Y are independently selected from N or CH; Z is selectedfrom the group consisting of hydrogen; halogen; linear, branched orcyclic saturated or unsaturated C₁C₆ alkyl; cyano; OR¹; —SR¹;NHR¹;—C(O)NHR¹; —NHC(O)R¹; —NHC(O)NHR¹; —S(O)R¹; and —S(O)₂R¹; G is selectedfrom the group consisting of halogen; 5- to 7-membered substituted orunsubstituted aryl; 5- to 7-membered substituted or unsubstitutedheteroaryl containing 1 to 3 heteroatom(s) selected from nitrogen,oxygen and sulfur; and a 5- to 7-membered substituted or unsubstitutedheterocyclic group containing 1 to 3 heteroatom(s) selected fromnitrogen, oxygen and sulfur; L1 is selected from the group consisting of5- to 7-membered substituted or unsubstituted aryl; biaryl resultingfrom two fused 5- to 7-membered substituted or unsubstituted aryls; 5-to 7-membered substituted or unsubstituted heteroaryl containing 1 to 3heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5- to7-membered substituted or unsubstituted heterocyclic group containing 1to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; L2 isnonexistent or selected from the group consisting of —NR²C(O)—;—C(O)NR²—; —NR²C(O)NR³—; —S(O)NR²—; and —S(O)₂NR²—; E is selected fromthe group consisting of hydrogen; linear, branched or cyclic saturatedor unsaturated C₁-C₆ alkyl; —NO₂; —OR³; —NR³R⁴; —NHC(O)R³; —C(O)OR³; 5-to 7-membered substituted or unsubstituted aryl; biaryl resulting fromtwo fused 5- to 7-membered substituted or unsubstituted aryls; 5- to7-membered substituted or unsubstituted heteroaryl containing 1 to 3heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5- to7-membered substituted or unsubstituted heterocyclic group containing 1to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; R¹ isselected from the group consisting of hydrogen; linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; saturated or unsaturatedC₁-C₆ alkyl substituted with heteroaryl or heterocyclic ring selectedfrom the group consisting of pyrrolidinonyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl and aziridinyl; R², R³ and R⁴ are independentlyselected from the group consisting of hydrogen; and linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; wherein the above aryl,heteroaryl, biaryl or heterocyclic is independently substituted orunsubstituted with 1 to 3 substituent(s) selected from the groupconsisting of hydrogen; halogen; linear, branched or cyclic saturated orunsaturated C₁-C₆ alkyl; C₁-C₆ haloalkyl containing 1 to 10 halogenatoms; cyano; —NO₂; —OBoc; —OR⁵; —O(CH₂)_(n)NR⁶R⁷ (where n is an integerfrom 1 to 6 ); —NR⁶R⁷; —NR⁵COR⁶; —NR⁵C(O)NR⁶R⁷; —C(O)R⁶; —C(O)OR⁶;—C(O)NR⁶R⁷; —C(O)NH(CH₂)_(n)NR⁶R⁷; —S(O)R⁶; —S(O)₂R⁶; —S(O)₂NR⁶R⁷; 5- to7-membered aryl; biaryl resulting from two fused 5- to 7-membered aryls;5- to 7-membered heteroaryl containing 1 to 3 heteroatom(s) selectedfrom nitrogen, oxygen and sulfur; and a 5- to 7-membered heterocyclicring containing 1 to 3 heteroatom(s) selected from nitrogen, oxygen andsulfur; and R⁵, R⁶ and R⁷ are independently selected from the groupconsisting of hydrogen; halogen; linear, branched or cyclic saturated orunsaturated C₁-C₆ alkyl; 5- to 7-membered aryl; biaryl resulting fromtwo fused 5- to 7-membered aryls; 5- to 7-membered heteroaryl containing1 to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5-to 7-membered heterocyclic ring containing 1 to 3 heteroatom(s) selectedfrom nitrogen, oxygen and sulfur; or NR⁶R⁷ forms a 5- to 7-memberedheteroaryl or a heterocyclic ring by further including 1 to 3 otherheteroatom(s); wherein the aryl, biaryl, heteroaryl or heterocyclic ringmay be substituted with 1 to 3 substituent(s) selected from the groupconsisting of halogen, C₁-C₆ alkyl, and C₁-C₆ haloalkyl containing 1 to10 halogen atom(s).
 2. A method of treating cancers selected from thegroup consisting of stomach cancer, non-small cell lung cancer, livercancer, colorectal cancer, small intestine cancer, pancreatic cancer,brain cancer metastasized from breast cancer, bone cancer, melanoma,breast cancer, sclerosing adenoma, ovarian cancer, cervical cancer, headand neck cancer, esophageal cancer, thyroid cancer, parathyroid cancer,renal cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer,leukemia, multiple myeloma, non-Hodgkin's lymphoma and fibroadenoma, themethod comprising administering, to a patient in need thereof, apharmaceutical composition comprising an active ingredient that is a1,3,6-substituted indole compound represented by Chemical Formula 1, ora pharmaceutically acceptable salt thereof:

wherein X and Y are independently selected from N or CH; Z is selectedfrom the group consisting of hydrogen; halogen; linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; cyano; OR¹; —SR¹;NHR¹;—C(O)NHR¹; —NHC(O)R¹; —NHC(O)NHR¹; —S(O)R¹; and —S(O)₂R¹; G is selectedfrom the group consisting of halogen; 5- to 7-membered substituted orunsubstituted aryl; 5- to 7-membered substituted or unsubstitutedheteroaryl containing 1 to 3 heteroatom(s) selected from nitrogen,oxygen and sulfur; and a 5- to 7-membered substituted or unsubstitutedheterocyclic group containing 1 to 3 heteroatom(s) selected fromnitrogen, oxygen and sulfur; L1 is selected from the group consisting of5- to 7-membered substituted or unsubstituted aryl; biaryl resultingfrom two fused 5- to 7-membered substituted or unsubstituted aryls; 5-to 7-membered substituted or unsubstituted heteroaryl containing 1 to 3heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5- to7-membered substituted or unsubstituted heterocyclic group containing 1to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; L2 isnonexistent or selected from the group consisting of —NR²C(O)—;—C(O)NR²—; —NR²C(O)NR³—; —S(O)NR²—; and —S(O)₂NR²—; E is selected fromthe group consisting of hydrogen; linear, branched or cyclic saturatedor unsaturated C₁-C₆ alkyl; —NO₂; —OR³; —NR³R⁴; —NHC(O)R³; —C(O)OR³; 5-to 7-membered substituted or unsubstituted aryl; biaryl resulting fromtwo fused 5- to 7-membered substituted or unsubstituted aryls; 5- to7-membered substituted or unsubstituted heteroaryl containing 1 to 3heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5- to7-membered substituted or unsubstituted heterocyclic group containing 1to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; R¹ isselected from the group consisting of hydrogen; linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; saturated or unsaturatedC₁-C₆ alkyl substituted with heteroaryl or heterocyclic ring selectedfrom the group consisting of pyrrolidinonyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl and aziridinyl; R², R³ and R⁴ are independentlyselected from the group consisting of hydrogen; and linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; wherein the above aryl,heteroaryl, biaryl or heterocyclic is independently substituted orunsubstituted with 1 to 3 substituent(s) selected from the groupconsisting of hydrogen; halogen; linear, branched or cyclic saturated orunsaturated C₁-C₆ alkyl; C₁-C₆ haloalkyl containing 1 to 10 halogenatoms; cyano; —NO₂; —OBoc; —OR⁵; —O(CH₂)_(n)NR⁶R⁷ (where n is an integerfrom 1 to 6 ); —NR⁶R⁷; —NR⁵COR⁶; —NR⁵C(O)NR⁶R⁷; —C(O)R⁶; —C(O)OR⁶;—C(O)NR⁶R⁷; —C(O)NH(CH₂)_(n)NR⁶R⁷; —S(O)R⁶; —S(O)₂R⁶; —S(O)₂NR⁶R⁷; 5- to7-membered aryl; biaryl resulting from two fused 5- to 7-membered aryls;5- to 7-membered heteroaryl containing 1 to 3 heteroatom(s) selectedfrom nitrogen, oxygen and sulfur; and a 5- to 7-membered heterocyclicring containing 1 to 3 heteroatom(s) selected from nitrogen, oxygen andsulfur; and R⁵, R⁶ and R⁷ are independently selected from the groupconsisting of hydrogen; halogen; linear, branched or cyclic saturated orunsaturated C₁-C₆ alkyl; 5- to 7-membered aryl; biaryl resulting fromtwo fused 5- to 7-membered aryls; 5- to 7-membered heteroaryl containing1 to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5-to 7-membered heterocyclic ring containing 1 to 3 heteroatom(s) selectedfrom nitrogen, oxygen and sulfur; or NR⁶R⁷ forms a 5- to 7-memberedheteroaryl or a heterocyclic ring by further including 1 to 3 otherheteroatom(s); wherein the aryl, biaryl, heteroaryl or heterocyclic ringmay be substituted with 1 to 3 substituent(s) selected from the groupconsisting of halogen, C₁-C₆ alkyl, and C₁-C₆ haloalkyl containing 1 to10 halogen atom(s).
 3. A method of treating melanoma, the methodcomprising administering, to a patient in need thereof, a pharmaceuticalcomposition comprising an active ingredient that is a 1,3,6-substitutedindole compound represented by Chemical Formula 1, or a pharmaceuticallyacceptable salt thereof:

wherein X and Y are independently selected from N or CH; Z is selectedfrom the group consisting of hydrogen; halogen; linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; cyano; OR —SR¹;NHR¹;—C(O)NHR¹; —NHC(O)R¹; —NHC(O)NHR¹; —S(O)R¹; and —S(O)₂R¹; G is selectedfrom the group consisting of halogen; 5- to 7-membered substituted orunsubstituted aryl; 5- to 7-membered substituted or unsubstitutedheteroaryl containing 1 to 3 heteroatom(s) selected from nitrogen,oxygen and sulfur; and a 5- to 7-membered substituted or unsubstitutedheterocyclic group containing 1 to 3 heteroatom(s) selected fromnitrogen, oxygen and sulfur; L1 is selected from the group consisting of5- to 7-membered substituted or unsubstituted aryl; biaryl resultingfrom two fused 5- to 7-membered substituted or unsubstituted aryls; 5-to 7-membered substituted or unsubstituted heteroaryl containing 1 to 3heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5- to7-membered substituted or unsubstituted heterocyclic group containing 1to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; L2 isnonexistent or selected from the group consisting of —NR²C(O)—;—C(O)NR²—; —NR²C(O)NR³—; —S(O)NR²—; and —S(O)₂NR²—; E is selected fromthe group consisting of hydrogen; linear, branched or cyclic saturatedor unsaturated C₁-C₆ alkyl; —NO₂; —OR³; —NR³R⁴; —NHC(O)R³; —C(O)OR³; 5-to 7-membered substituted or unsubstituted aryl; biaryl resulting fromtwo fused 5- to 7-membered substituted or unsubstituted aryls; 5- to7-membered substituted or unsubstituted heteroaryl containing 1 to 3heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5- to7-membered substituted or unsubstituted heterocyclic group containing 1to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; R¹ isselected from the group consisting of hydrogen; linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; saturated or unsaturatedC₁-C₆ alkyl substituted with heteroaryl or heterocyclic ring selectedfrom the group consisting of pyrrolidinonyl, pyrrolidinyl, piperidinyl,piperazinyl, morpholinyl and aziridinyl; R², R³ and R⁴ are independentlyselected from the group consisting of hydrogen; and linear, branched orcyclic saturated or unsaturated C₁-C₆ alkyl; wherein the above aryl,heteroaryl, biaryl or heterocyclic is independently substituted orunsubstituted with 1 to 3 substituent(s) selected from the groupconsisting of hydrogen; halogen; linear, branched or cyclic saturated orunsaturated C₁-C₆ alkyl; C₁-C₆ haloalkyl containing 1 to 10 halogenatoms; cyano; —NO₂; —OBoc; —OR⁵; —O(CH₂)_(n)NR⁶R⁷ (where n is an integerfrom 1 to 6 ); —NR⁶R⁷; —NR⁵COR⁶; —NR⁵C(O)NR⁶R⁷; —C(O)R⁶; —C(O)OR⁶;—C(O)NR⁶R⁷; —C(O)NH(CH₂)_(n)NR⁶R⁷; —S(O)R⁶; —S(O)₂R⁶; —S(O)₂NR⁶R⁷; 5- to7-membered aryl; biaryl resulting from two fused 5- to 7-membered aryls;5- to 7-membered heteroaryl containing 1 to 3 heteroatom(s) selectedfrom nitrogen, oxygen and sulfur; and a 5- to 7-membered heterocyclicring containing 1 to 3 heteroatom(s) selected from nitrogen, oxygen andsulfur; and R⁵, R⁶ and R⁷ are independently selected from the groupconsisting of hydrogen; halogen; linear, branched or cyclic saturated orunsaturated C₁-C₆ alkyl; 5- to 7-membered aryl; biaryl resulting fromtwo fused 5- to 7-membered aryls; 5- to 7-membered heteroaryl containing1 to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur; and a 5-to 7-membered heterocyclic ring containing 1 to 3 heteroatom(s) selectedfrom nitrogen, oxygen and sulfur; or NR⁶R⁷ forms a 5- to 7-memberedheteroaryl or a heterocyclic ring by further including 1 to 3 otherheteroatom(s); wherein the aryl, biaryl, heteroaryl or heterocyclic ringmay be substituted with 1 to 3 substituent(s) selected from the groupconsisting of halogen, C₁-C₆ alkyl, and C₁-C₆ haloalkyl containing 1 to10 halogen atom(s).